ClinicalTrials.gg
CompletedNCT03158285Updated Jun 2, 2026Results posted

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 138 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
741
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
2nd of 14
741 · median 173
Started
2017
with 1 other
Phase 3
7 of 14
1 open now
Registered
2nd of 14
by date
Lead sponsor
9 of 14
Janssen Research & Development, LLC

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 2nd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Read the detailed description

This is a study of guselkumab in participants with active PsA who are biologically naive and have had inadequate response to standard therapies. It will evaluate the clinical efficacy of guselkumab in the reduction of signs and symptoms, structural damage inhibition and the safety profile of guselkumab in the treatment of PsA. The study will consist of a screening phase (up to 6 weeks), a blinded treatment phase (approximately 100 weeks) including a placebo controlled period from Week 0 to Week 24 and an active treatment period from Week 24 to Week 100 and a safety follow-up phase of 12 weeks after the last administration of study agent. Efficacy, health economics, safety, pharmacokinetics, immunogenicity, biomarker and pharmacogenomics evaluations will be performed in the study at defined schedule.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of Psoriatic Arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening
  • Have active PsA as defined by: at least 5 swollen joints and at least 5 tender joints at screening and at baseline, and CRP greater than or equal to (>=) 0.6 milligram per deciLitre (mg/dL) at screening from the central laboratory
  • Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis (confirmation of sacroiliitis should be performed at the screening visit by a locally performed pelvic x-ray [single anterior-posterior view] unless a pelvic or SI joint x-ray or pelvic magnetic resonance imaging (MRI) has been previously performed. Results must be documented)
  • Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeter (cm) diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis
  • Have active PsA despite previous non-biologic disease-modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy

Exclusion criteria

Exclusion Criteria:

  • Has other inflammatory diseases that might confound the evaluations or benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has previously received any biologic treatment
  • Has ever received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX-509), or any other Janus kinase (JAK) inhibitor
  • Has received any systemic (eg, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study agent
  • Is currently receiving 2 or more non-biologic DMARDs (other than methotrexate [MTX], sulfasalazine [SSZ], Hydroxychloroquine [HCQ], leflunomide [LEF]) including, but not limited to chloroquine, gold preparations, and penicillamine within 4 weeks before the first administration of study agent
  • Has received apremilast within 4 weeks prior to the first administration of study agent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
741 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.

    Drug: Guselkumab

  • Experimental
    Group 2: Guselkumab and Placebo

    Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Experimental
    Group 3: Placebo Followed by Guselkumab

    Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.

    Also known as: CNTO 1959

  • DrugPlacebo

    Participants will receive matching placebo as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

    ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Who Achieved an ACR 50 Response at Week 24

    ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).

    Time frame: Week 24

  3. Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline

    A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 24

  4. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16

    ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Week 16

  5. Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline and Week 24

  6. Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

    Time frame: Week 24

  7. Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

    Time frame: Week 24

  8. Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

    Time frame: Baseline and Week 24

  9. Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

    Time frame: Baseline and Week 24

  10. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline and Week 24

  11. Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24

    The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

    Time frame: Baseline and Week 24

  12. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline and Week 24

  13. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16

    ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Week 16

  14. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24

    ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Week 24

  15. Percentage of Participants Who Achieved ACR 20 Response Through Week 24

    ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  16. Percentage of Participants Who Achieved ACR 50 Response Through Week 24

    ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  17. Percentage of Participants Who Achieved ACR 70 Response Through Week 24

    ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  18. Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \[mg/dL\]).

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  19. Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24

    HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  20. Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline

    HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  21. Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  22. Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  23. Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24

  24. Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24

    The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  25. Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

    Time frame: Weeks 2, 4, 8, 16 and 24

  26. Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

    Time frame: Weeks 2, 4, 8, 16 and 24

  27. Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

    Time frame: Baseline, Weeks 2, 4, 8, 16 and 24

  28. Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.

    Time frame: Baseline, Weeks 2, 4, 8, 16 and 24

  29. Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

    Time frame: Baseline, Weeks 8, 16 and 24

  30. Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24

    GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

    Time frame: Baseline, Weeks 16 and 24

  31. Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 16 and 24

  32. Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 16 and 24

  33. Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 16 and 24

  34. Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 16 and 24

  35. Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24

    The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

    Time frame: Baseline, Weeks 16 and 24

  36. Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24

    DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24

  37. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24

    MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

    Time frame: Weeks 16 and 24

  38. Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Weeks 8, 16 and 24

  39. Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.

    Time frame: Weeks 16 and 24

  40. Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

    Time frame: Weeks 16 and 24

  41. Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.

    Time frame: Weeks 16 and 24

  42. Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 16 and 24

  43. Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

    Time frame: Baseline, Weeks 16 and 24

  44. Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

    Time frame: Weeks 8, 16, 24

  45. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

    Time frame: Weeks 8, 16, 24

  46. Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

    Time frame: Baseline, Weeks 8, 16 and 24

  47. Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

    Time frame: Weeks 16 and 24

  48. Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

    Time frame: Weeks 16 and 24

  49. Change From Baseline in Modified vdH-S Erosion Score at Week 24

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline and Week 24

  50. Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24

    The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.

    Time frame: Baseline and Week 24

  51. Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24

    Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

    Time frame: Baseline and Week 24

  52. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Week 24

  53. Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Week 24

  54. Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24

    The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \<=0 (assessed by both readers) or \<=0.5 (assessed by at least one reader) was considered as no progression of JSN.

    Time frame: Week 24

  55. Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24

    Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.18.

    Time frame: Week 24

  56. Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24

    Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 1.83.

    Time frame: Week 24

  57. Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24

    The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.11.

    Time frame: Week 24

  58. Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24

    Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

    Time frame: Baseline and Week 24

  59. Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 8, 16 and 24

  60. Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 8, 16 and 24

  61. Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline and Weeks 8, 16 and 24

  62. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Week 8, 16 and 24

  63. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Week 8, 16 and 24

  64. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline, Weeks 8, 16 and 24

  65. Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Weeks 8, 16 and 24

  66. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status

    Time frame: Baseline, Weeks 16 and 24

  67. Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

    Time frame: Baseline, Weeks 16 and 24

  68. Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 24, 28, 36, 44 and 52

  69. Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 24, 28, 36, 44 and 52

  70. Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 24, 28, 36, 44 and 52

  71. ACR Components at Weeks 24, 28, 36, 44 and 52

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

    Time frame: Weeks 24, 28, 36, 44 and 52

  72. Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  73. Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  74. Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 52

  75. Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 52

  76. Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 52

  77. Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  78. Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Weeks 24, 28, 36, 44 and 52

  79. Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Week 52

  80. Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

    Time frame: Weeks 24, 28, 36, 44 and 52

  81. Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.

    Time frame: Weeks 24, 28, 36, 44 and 52

  82. Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  83. Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52

    The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

    Time frame: Weeks 24, 28, 36, 44 and 52

  84. Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

    Time frame: Weeks 24 and 52

  85. Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

    Time frame: Baseline, Weeks 24 and 52

  86. Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

    Time frame: Weeks 24 and 52

  87. Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

    Time frame: Baseline, Weeks 24 and 52

  88. Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

    Time frame: Baseline, Weeks 24 and 52

  89. Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

    Time frame: Weeks 24 and 52

  90. Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

    GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

    Time frame: Baseline, Weeks 24 and 52

  91. Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

    GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.

    Time frame: Weeks 24 and 52

  92. Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52

    DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  93. Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

    The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

    Time frame: Baseline, Weeks 24 and 52

  94. Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

    The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.

    Time frame: Weeks 24 and 52

  95. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52

    MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

    Time frame: Weeks 24 and 52

  96. Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52

    A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

    Time frame: Weeks 24 and 52

  97. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Baseline, Weeks 24 and 52

  98. Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Weeks 24 and 52

  99. Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

    Time frame: Baseline, Weeks 24 and 52

  100. Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  101. Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  102. Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  103. Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  104. Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

    Time frame: Weeks 24 and 52

  105. Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

    Time frame: Weeks 24 and 52

  106. Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 24 and 52

  107. Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 24 and 52

  108. Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

    Time frame: Weeks 24 and 52

  109. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

    Time frame: Weeks 24 and 52

  110. Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

    Time frame: Baseline, Weeks 24 and 52

  111. Change From Baseline in Modified vdH-S Score at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline and Week 52

  112. Change in Total Modified vdH-S Score From Week 24 to Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

    Time frame: From Week 24 to Week 52

  113. Change From Baseline in Modified vdH-S Erosion Score at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline and Week 52

  114. Change in Modified vdH-S Erosion Score From Week 24 to Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

    Time frame: From Week 24 to Week 52

  115. Change From Baseline in Modified vdH-S JSN Score at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline and Week 52

  116. Change in Modified vdH-S JSN Score From Week 24 to Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

    Time frame: From Week 24 to Week 52

  117. Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

    Time frame: Baseline and Week 52

  118. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Week 52

  119. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Week 52

  120. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Week 52

  121. Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52

    Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.39.

    Time frame: Week 52

  122. Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52

    Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 2.22.

    Time frame: Week 52

  123. Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52

    Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \<=SDC of 1.02.

    Time frame: Week 52

  124. Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52

    Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

    Time frame: Baseline and Week 52

  125. Change From Baseline in SF-36 PCS Score at Weeks 24 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 24 and 52

  126. Change From Baseline in SF-36 MCS Score at Weeks 24 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 24 and 52

  127. Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 24 and 52

  128. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 24 and 52

  129. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 24 and 52

  130. Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline, Weeks 24 and 52

  131. Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Weeks 24 and 52

  132. Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.

    Time frame: Baseline, Weeks 24 and 52

  133. Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

    Time frame: Baseline, Weeks 24 and 52

  134. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 24 and 52

  135. Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 24 and 52

  136. Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 24 and 52

  137. Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 24 and 52

  138. Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 52, 68, 76, 84 and 100

  139. Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 52, 68, 76, 84 and 100

  140. Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 52, 68, 76, 84 and 100

  141. ACR Components at Weeks 52, 68, 76, 84 and 100

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

    Time frame: Weeks 52, 68, 76, 84 and 100

  142. Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

    Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

  143. Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

    Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

  144. Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 100

  145. Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 100

  146. Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 100

  147. Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

  148. Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Weeks 52, 68, 76, 84 and 100

  149. Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Week 100

  150. Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

    Time frame: Weeks 52, 68, 76, 84 and 100

  151. Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.

    Time frame: Weeks 52, 68, 76, 84 and 100

  152. Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

    Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

  153. Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100

    The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

    Time frame: Weeks 52, 68, 76, 84 and 100

  154. Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

    Time frame: Weeks 52, 76, and 100

  155. Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

    Time frame: Baseline, Weeks 52, 76 and 100

  156. Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

    Time frame: Weeks 52, 76 and 100

  157. Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.

    Time frame: Baseline, Weeks 52, 76 and 100

  158. Change From Baseline in PASDAS Score at Weeks 52, 76 and 100

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

    Time frame: Baseline, Weeks 52, 76 and 100

  159. Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \<= 3.2; Very low: PASDAS \<= 1.9.

    Time frame: Weeks 52, 76 and 100

  160. Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100

    GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

    Time frame: Baseline, Weeks 52, 76 and 100

  161. Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100

    GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.

    Time frame: Weeks 52, 76 and 100

  162. Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100

    DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

  163. Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100

    DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\<=14; Remission: DAPSA\<=4.

    Time frame: Weeks 52, 68, 76, 84 and 100

  164. Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100

    The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

    Time frame: Baseline, Weeks 52, 76 and 100

  165. Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100

    The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.

    Time frame: Weeks 52, 76 and 100

  166. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100

    MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

    Time frame: Weeks 52, 76 and 100

  167. Percentage of Participants With VLDA at Weeks 52, 76 and 100

    A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

    Time frame: Weeks 52, 76 and 100

  168. Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Baseline, Weeks 52, 76 and 100

  169. Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Weeks 52, 76 and 100

  170. Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

    Time frame: Baseline, Weeks 52, 76 and 100

  171. Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.

    Time frame: Weeks 52, 76 and 100

  172. Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

    Time frame: Weeks 52, 76 and 100

  173. Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

    Time frame: Weeks 52, 76 and 100

  174. Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

    Time frame: Weeks 52, 76 and 100

  175. Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

    Time frame: Weeks 52, 76 and 100

  176. Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

    Time frame: Weeks 52, 76 and 100

  177. Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). IGA Response is defined as achieving IGA score of 0 or 1, and \>=2 grade reduction from baseline.

    Time frame: Weeks 52, 76 and 100

  178. Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 52, 76 and 100

  179. Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

    Time frame: Weeks 52, 76 and 100

  180. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

    Time frame: Weeks 52, 76 and 100

  181. Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

    Time frame: Baseline, Weeks 52, 76 and 100

  182. Change in Modified vdH-S Score From Baseline to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline to Week 100

  183. Change in Total Modified vdH-S Score From Week 52 to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

    Time frame: From Week 52 to Week 100

  184. Change in Modified vdH-s Erosion Score From Baseline to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline to Week 100

  185. Change in Modified vdH-s Erosion Score From Week 52 to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: From Week 52 to Week 100

  186. Change in Modified vdH-s JSN Score From Baseline to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline to Week 100

  187. Change in Modified vdH-s JSN Score From Week 52 to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: From Week 52 to Week 100

  188. Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)

    Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

    Time frame: Baseline to Week 100

  189. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline to Week 100

  190. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline to Week 100

  191. Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score

    Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

    Time frame: Baseline to Week 100

  192. Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100

    Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 3.46.

    Time frame: Baseline to Week 100

  193. Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100

    Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \<=SDC of 2.66.

    Time frame: Baseline to Week 100

  194. Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100

    Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.66.

    Time frame: Baseline to Week 100

  195. Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100

    Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

    Time frame: Baseline, Weeks 24, 52, and 100

  196. Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 52, 76 and 100

  197. Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 52, 76 and 100

  198. Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 52, 76 and 100

  199. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 52, 76 and 100

  200. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 52, 76 and 100

  201. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline, Weeks 52, 76 and 100

  202. Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Weeks 52, 76 and 100

  203. Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.

    Time frame: Baseline, Weeks 52, 76 and 100

  204. Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

    Time frame: Baseline, Weeks 52, 76 and 100

  205. Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 52, 76 and 100

  206. Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 52, 76 and 100

  207. Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 52, 76 and 100

  208. Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100

    Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

    Time frame: Baseline, Weeks 52, 76 and 100

07

Results

Posted Nov 5, 2020

Participant flow

Placebo-controlled Period: Week 0 - 24
Participant flow — Placebo-controlled Period: Week 0 - 24
MilestonePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started246248245
Pooled population: enthesitis assessment255230243
Pooled population: dactylitis assessment154160159
Completed240240236
Not completed689
Withdrew: Adverse event426
Withdrew: Lack of efficacy033
Withdrew: Withdrawal by subject110
Withdrew: Lost to follow-up010
Withdrew: Other110
Active Treatment Period: Week 24 - 52
Participant flow — Active Treatment Period: Week 24 - 52
MilestonePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started238240234
Completed228234227
Not completed1067
Withdrew: Adverse event301
Withdrew: Lack of efficacy534
Withdrew: Withdrawal by subject121
Withdrew: Pregnancy001
Withdrew: Other110
Active Treatment Period: Week 52-100
Participant flow — Active Treatment Period: Week 52-100
MilestonePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started228232227
Completed210223219
Not completed1898
Withdrew: Adverse event753
Withdrew: Lack of efficacy113
Withdrew: Withdrawal by subject521
Withdrew: Pregnancy001
Withdrew: Death100
Withdrew: Other410

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 2432.964.163.7
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 31.2 · 95% CI 22.9 to 39.5
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 30.8 · 95% CI 22.4 to 39.1
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24-0.1300 (-0.1912 to -0.0687)-0.3672 (-0.4282 to -0.3062)-0.4004 (-0.4617 to -0.3390)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 · Least square (ls) mean difference: -0.2372 · 95% CI -0.3210 to -0.1534
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = < 0.001 · Ls mean difference: -0.2704 · 95% CI -0.3544 to -0.1864
SecondaryPercentage of Participants Who Achieved an ACR 50 Response at Week 24

ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR 50 Response at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an ACR 50 Response at Week 2414.231.533.1
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 17.2 · 95% CI 10.0 to 24.4
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 18.8 · 95% CI 11.5 to 26.1
SecondaryPercentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline

A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline19.170.568.5
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage: 50.9 · 95% CI 42.2 to 59.7
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 49.8 · 95% CI 41.2 to 58.4
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16

ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 1633.755.255.9
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 21.5 · 95% CI 13.1 to 30.0
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 22.2 · 95% CI 13.7 to 30.7
SecondaryChange From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 240.95 (0.61 to 1.29)0.52 (0.18 to 0.86)0.29 (-0.05 to 0.63)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = 0.072 · Ls mean difference: -0.43 · 95% CI -0.90 to 0.03
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = 0.011 · Ls mean difference: -0.66 · 95% CI -1.13 to -0.19
SecondaryPercentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline29.449.644.9
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = 0.030 · Difference in response rates: 20.1 · 95% CI 11.8 to 28.5
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = 0.030 · Difference in response rates: 14.6 · 95% CI 6.4 to 22.7
SecondaryPercentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline42.259.463.5
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = 0.030 · Difference in response rates: 18.0 · 95% CI 7.4 to 28.6
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = 0.011 · Difference in response rates: 21.3 · 95% CI 10.5 to 32.0
SecondaryChange From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline-1.02 (-1.22 to -0.82)-1.52 (-1.73 to -1.31)-1.59 (-1.79 to -1.38)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -0.50 · 95% CI -0.77 to -0.23
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -0.57 · 95% CI -0.83 to -0.31
SecondaryChange From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline-4.21 (-5.05 to -3.36)-6.10 (-6.92 to -5.27)-5.97 (-6.84 to -5.11)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -1.89 · 95% CI -2.99 to -0.79
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = 0.002 (Nominal) · Ls mean difference: -1.77 · 95% CI -2.87 to -0.66
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 243.42 (2.53 to 4.32)7.39 (6.50 to 8.29)7.04 (6.14 to 7.94)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = 0.011 · Ls mean difference: 3.97 · 95% CI 2.75 to 5.20
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = 0.011 · Ls mean difference: 3.62 · 95% CI 2.39 to 4.85
SecondaryChange From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24

The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24-0.97 (-1.11 to -0.84)-1.59 (-1.72 to -1.45)-1.62 (-1.76 to -1.49)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -0.61 · 95% CI -0.80 to -0.43
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -0.65 · 95% CI -0.83 to -0.47
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 242.14 (1.07 to 3.22)4.17 (3.10 to 5.23)4.22 (3.14 to 5.29)
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · ANCOVA · p = 0.072 · Ls mean difference: 2.02 · 95% CI 0.56 to 3.49
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · ANCOVA · p = 0.072 · Ls mean difference: 2.07 · 95% CI 0.60 to 3.54
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16

ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 169.328.620.8
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 19.3 · 95% CI 12.6 to 25.9
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 11.5 · 95% CI 5.2 to 17.7
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24

ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 244.118.513.1
Statistical analysis
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 14.5 · 95% CI 9.1 to 19.9
  • Placebo to Guselkumab 100 mg q4w vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 9.0 · 95% CI 4.1 to 13.8
SecondaryPercentage of Participants Who Achieved ACR 20 Response Through Week 24

ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20 Response Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 28.110.110.6
Week 411.819.821.6
Week 817.539.140.0
Week 1226.449.651.0
Week 1633.755.255.9
Week 2029.762.958.8
Week 2432.964.163.7
SecondaryPercentage of Participants Who Achieved ACR 50 Response Through Week 24

ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50 Response Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 20.41.60.4
Week 41.24.03.3
Week 84.110.111.0
Week 126.119.016.7
Week 169.328.620.8
Week 2016.331.529.8
Week 2414.231.533.1
SecondaryPercentage of Participants Who Achieved ACR 70 Response Through Week 24

ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70 Response Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2000
Week 40.80.40.8
Week 80.83.62.0
Week 120.48.14.9
Week 160.813.78.2
Week 203.315.313.9
Week 244.118.513.1
SecondaryPercent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \[mg/dL\]).

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Mean · percent change
Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24
percent changePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2: Swollen Joint Count-18.9 ± 32.16-18.8 ± 39.68-18.5 ± 38.38
Week 4: Swollen Joint Count-27.1 ± 37.29-30.5 ± 36.92-33.6 ± 37.57
Week 8: Swollen Joint Count-37.4 ± 39.03-46.8 ± 40.68-46.7 ± 37.69
Week 12: Swollen Joint Count-46.1 ± 41.20-57.6 ± 39.22-58.3 ± 35.42
Week 16: Swollen Joint Count-48.6 ± 43.01-64.1 ± 35.46-63.7 ± 34.42
Week 20: Swollen Joint Count-54.2 ± 41.70-69.3 ± 33.63-71.4 ± 30.42
Week 24: Swollen Joint Count-53.9 ± 45.54-71.3 ± 34.06-73.1 ± 30.67
Week 2: Tender Joint Count-9.4 ± 25.99-10.4 ± 40.31-14.8 ± 28.31
Week 4: Tender Joint Count-14.1 ± 36.04-15.0 ± 41.57-22.6 ± 32.91
Week 8: Tender Joint Count-21.9 ± 37.83-31.0 ± 42.36-33.8 ± 37.58
Week 12: Tender Joint Count-30.4 ± 37.57-40.9 ± 42.73-43.0 ± 35.90
Week 16: Tender Joint Count-30.6 ± 41.87-47.0 ± 40.96-48.1 ± 37.01
Week 20: Tender Joint Count-33.9 ± 44.22-53.9 ± 37.83-54.2 ± 35.43
Week 24: Tender Joint Count-33.3 ± 44.87-54.2 ± 37.15-57.3 ± 34.98
Week 2: Patient's Assessment of Pain0.05 ± 35.794-8.92 ± 32.374-4.66 ± 32.229
Week 4: Patient's Assessment of Pain-0.64 ± 35.849-12.58 ± 33.065-7.96 ± 37.958
Week 8: Patient's Assessment of Pain-6.76 ± 34.213-21.61 ± 36.705-17.05 ± 44.783
Week 12: Patient's Assessment of Pain-9.01 ± 36.061-26.26 ± 40.223-25.91 ± 37.862
Week 16: Patient's Assessment of Pain(0-10cm)-9.70 ± 41.673-31.94 ± 42.882-27.85 ± 38.913
Week 20: Patient's Assessment of Pain-10.85 ± 46.497-35.16 ± 39.471-35.35 ± 39.016
Week 24: Patient's Assessment of Pain-11.84 ± 48.324-38.06 ± 40.565-36.52 ± 38.423
Week 2: PtGA of Disease Activity-1.12 ± 35.882-10.15 ± 31.060-5.25 ± 32.658
Week 4: PtGA of Disease Activity-2.27 ± 34.291-12.71 ± 34.440-11.02 ± 33.605
Week 8: PtGA of Disease Activity-6.51 ± 35.908-21.58 ± 33.697-19.13 ± 40.545
Week 12: PtGA of Disease Activity-9.30 ± 37.185-27.86 ± 38.900-28.33 ± 34.058
Week 16: PtGA of Disease Activity-12.34 ± 39.207-32.25 ± 40.056-28.60 ± 39.759
Week 20: PtGA of Disease Activity-12.52 ± 42.498-35.31 ± 36.205-35.11 ± 37.791
Week 24: PtGA of Disease Activity-13.87 ± 45.650-37.05 ± 38.372-34.13 ± 51.445
Week 2: PGA of Disease Activity-9.79 ± 25.687-15.06 ± 27.150-13.85 ± 23.307
Week 4: PGA of Disease Activity-16.63 ± 27.573-23.72 ± 27.658-22.32 ± 28.183
Week 8: PGA of Disease Activity-23.29 ± 28.416-36.54 ± 31.224-37.99 ± 29.970
Week 12: PGA of Disease Activity-27.63 ± 32.379-46.54 ± 30.489-42.84 ± 31.305
Week 16: PGA of Disease Activity-31.11 ± 32.023-52.02 ± 31.915-49.18 ± 31.383
Week 20: PGA of Disease Activity-34.13 ± 36.576-54.32 ± 30.941-54.59 ± 29.336
Week 24: PGA of Disease Activity-36.59 ± 33.740-57.22 ± 32.480-58.70 ± 28.255
Week 2: HAQ-DI Score-0.3191 ± 36.62364-6.3577 ± 50.81980-0.2385 ± 57.44896
Week 4: HAQ-DI Score-2.8744 ± 46.90795-9.1272 ± 53.41051-5.1209 ± 85.16625
Week 8: HAQ-DI Score-5.0965 ± 39.89566-12.7684 ± 67.23239-9.8081 ± 86.78973
Week 12: HAQ-DI Score-8.0811 ± 46.90093-18.0336 ± 66.96524-17.7758 ± 67.44643
Week 16: HAQ-DI Score-7.1776 ± 48.33253-19.3627 ± 70.83578-26.6732 ± 53.14973
Week 20: HAQ-DI Score-10.4296 ± 50.87958-24.9496 ± 64.86820-28.9317 ± 60.67279
Week 24: HAQ-DI Score-6.7995 ± 54.78602-25.2578 ± 63.15450-33.8837 ± 51.59441
Week 2: CRP86.677 ± 645.02810.935 ± 91.378310.664 ± 132.5947
Week 4: CRP28.042 ± 208.6385-16.885 ± 79.35011.128 ± 168.9301
Week 8: CRP45.451 ± 322.4433-11.214 ± 150.1689-17.474 ± 112.3803
Week 12: CRP47.034 ± 313.9875-25.620 ± 97.1384-22.277 ± 122.3489
Week 16: CRP28.595 ± 237.6660-19.874 ± 134.5210-26.592 ± 86.8465
Week 20: CRP42.282 ± 284.1330-13.551 ± 193.3814-28.701 ± 83.0912
Week 24: CRP19.263 ± 149.5120-27.470 ± 109.5239-28.125 ± 87.7229
SecondaryChange From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24

HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2-0.0594 (-0.1023 to -0.0165)-0.1423 (-0.1850 to -0.0997)-0.0795 (-0.1226 to -0.0364)
Week 4-0.0722 (-0.1196 to -0.0247)-0.1472 (-0.1944 to -0.1000)-0.1605 (-0.2081 to -0.1128)
Week 8-0.0942 (-0.1464 to -0.0420)-0.2294 (-0.2815 to -0.1773)-0.2336 (-0.2859 to -0.1813)
Week 12-0.1332 (-0.1875 to -0.0790)-0.2870 (-0.3411 to -0.2330)-0.3010 (-0.3554 to -0.2466)
Week 16-0.1167 (-0.1753 to -0.0582)-0.3177 (-0.3760 to -0.2595)-0.3442 (-0.4029 to -0.2855)
Week 20-0.1565 (-0.2163 to -0.0968)-0.3536 (-0.4131 to -0.2941)-0.4019 (-0.4618 to -0.3420)
Week 24-0.1300 (-0.1912 to -0.0687)-0.3672 (-0.4282 to -0.3062)-0.4004 (-0.4617 to -0.3390)
SecondaryPercentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 219.930.723.2
Week 423.732.035.1
Week 828.043.442.5
Week 1231.847.446.9
Week 1630.950.051.8
Week 2038.648.753.1
Week 2431.450.056.1
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 221.523.824.5
Week 432.938.740.8
Week 838.656.954.7
Week 1251.267.365.7
Week 1651.269.872.7
Week 2050.475.076.3
Week 2452.475.480.0
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 20.82.42.4
Week 42.05.24.9
Week 80.810.59.0
Week 126.114.111.8
Week 166.518.516.3
Week 209.823.021.2
Week 248.524.623.3
SecondaryChange From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2-0.29 (-0.37 to -0.21)-0.42 (-0.50 to -0.33)-0.43 (-0.51 to -0.35)
Week 4-0.44 (-0.53 to -0.35)-0.62 (-0.71 to -0.53)-0.65 (-0.74 to -0.55)
Week 8-0.59 (-0.71 to -0.48)-0.99 (-1.11 to -0.88)-0.98 (-1.09 to -0.86)
Week 12-0.85 (-0.97 to -0.73)-1.27 (-1.39 to -1.15)-1.22 (-1.35 to -1.10)
Week 16-0.88 (-1.01 to -0.75)-1.39 (-1.52 to -1.26)-1.37 (-1.50 to -1.24)
Week 20-1.00 (-1.13 to -0.87)-1.52 (-1.65 to -1.38)-1.56 (-1.70 to -1.43)
Week 24-0.97 (-1.11 to -0.84)-1.59 (-1.72 to -1.45)-1.62 (-1.76 to -1.49)
SecondaryPercentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24

The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 213.022.218.0
Week 427.232.729.8
Week 835.848.850.2
Week 1240.760.960.8
Week 1644.766.566.5
Week 2046.772.269.0
Week 2444.772.668.6
SecondaryPercentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame:
Weeks 2, 4, 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 216.317.717.1
Week 418.021.525.3
Week 824.731.027.6
Week 1630.947.540.6
Week 2430.353.843.5
SecondaryPercentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame:
Weeks 2, 4, 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 212.113.513.2
Week 418.219.820.7
Week 829.330.631.4
Week 1636.445.052.1
Week 2438.456.863.6
SecondaryChange From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

Time frame:
Baseline, Weeks 2, 4, 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2-0.33 (-0.53 to -0.12)-0.37 (-0.59 to -0.16)-0.49 (-0.70 to -0.29)
Week 4-0.46 (-0.68 to -0.24)-0.56 (-0.79 to -0.33)-0.69 (-0.92 to -0.47)
Week 8-0.67 (-0.90 to -0.45)-0.92 (-1.16 to -0.67)-0.88 (-1.11 to -0.64)
Week 16-0.94 (-1.18 to -0.71)-1.37 (-1.62 to -1.12)-1.42 (-1.66 to -1.18)
Week 24-1.03 (-1.25 to -0.81)-1.60 (-1.84 to -1.37)-1.52 (-1.75 to -1.29)
SecondaryChange From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.

Time frame:
Baseline, Weeks 2, 4, 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2-0.21 (-1.11 to 0.69)-1.11 (-1.95 to -0.26)-0.78 (-1.61 to 0.05)
Week 4-1.10 (-2.07 to -0.13)-2.11 (-3.02 to -1.20)-1.56 (-2.47 to -0.66)
Week 8-2.17 (-3.19 to -1.16)-3.17 (-4.12 to -2.22)-3.11 (-4.05 to -2.17)
Week 16-3.40 (-4.42 to -2.38)-4.88 (-5.84 to -3.92)-4.80 (-5.75 to -3.85)
Week 24-4.03 (-4.96 to -3.10)-5.95 (-6.83 to -5.08)-5.88 (-6.74 to -5.01)
SecondaryChange From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8-0.863 (-1.007 to -0.719)-1.452 (-1.595 to -1.309)-1.413 (-1.557 to -1.270)
Week 16-1.158 (-1.327 to -0.988)-2.110 (-2.278 to -1.942)-1.994 (-2.164 to -1.825)
Week 24-1.336 (-1.516 to -1.156)-2.403 (-2.582 to -2.225)-2.399 (-2.579 to -2.219)
SecondaryChange From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-1.029 (-1.212 to -0.847)-2.326 (-2.507 to -2.145)-2.214 (-2.397 to -2.032)
Week 24-1.198 (-1.395 to -1.001)-2.593 (-2.789 to -2.397)-2.589 (-2.786 to -2.392)
SecondaryChange From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · percentage of work time missed
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24
percentage of work time missedPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-4.553 (-7.199 to -1.906)-3.451 (-6.199 to -0.703)-4.717 (-7.449 to -1.985)
Week 24-3.491 (-6.403 to -0.578)-3.103 (-6.062 to -0.144)-3.827 (-6.826 to -0.828)
SecondaryChange From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · percentage of impairment
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24
percentage of impairmentPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-10.281 (-13.887 to -6.675)-16.054 (-19.699 to -12.409)-15.083 (-18.655 to -11.511)
Week 24-10.157 (-13.663 to -6.650)-19.366 (-22.857 to -15.875)-19.492 (-22.982 to -16.003)
SecondaryChange From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · percentage of overall work impairment
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24
percentage of overall work impairmentPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-11.232 (-14.962 to -7.501)-15.926 (-19.694 to 12.159)-15.808 (-19.501 to -12.115)
Week 24-10.869 (-14.591 to -7.147)-19.711 (-23.416 to -16.006)-20.023 (-23.726 to -16.320)
SecondaryChange From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · percentage of activity impairment
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24
percentage of activity impairmentPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-10.569 (-13.262 to -7.877)-17.107 (-19.787 to -14.428)-17.029 (-19.727 to -14.331)
Week 24-10.320 (-13.071 to -7.570)-21.467 (-24.204 to -18.729)-20.480 (-23.226 to -17.734)
SecondaryChange From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24

The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-1.18 (-1.43 to -0.93)-2.39 (-2.64 to -2.14)-2.57 (-2.82 to -2.31)
Week 24-1.30 (-1.57 to -1.04)-2.94 (-3.20 to -2.68)-3.09 (-3.35 to -2.83)
SecondaryChange From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2-4.6447 (-5.9287 to -3.3607)-6.7838 (-8.0642 to -5.5034)-6.3783 (-7.6664 to -5.0902)
Week 4-7.6695 (-9.2194 to -6.1197)-9.9687 (-11.5128 to -8.4246)-10.2484 (-11.8049 to -8.6919)
Week 8-10.4480 (-12.1877 to -8.7084)-15.3303 (-17.0682 to -13.5924)-15.8657 (-17.6038 to -14.1277)
Week 12-14.2915 (-16.1107 to -12.4724)-18.9772 (-20.7912 to -17.1632)-19.9687 (-21.7915 to -18.1459)
Week 16-14.8556 (-16.8664 to -12.8448)-21.6939 (-23.6979 to -19.6899)-21.4722 (-23.4873 to -19.4571)
Week 20-16.1375 (-18.1165 to -14.1586)-23.3163 (-25.2890 to -21.3436)-24.6844 (-26.6691 to -22.6997)
Week 24-15.8489 (-17.9229 to -13.7750)-24.0359 (-26.1019 to -21.9699)-25.1583 (-27.2341 to -23.0824)
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24

MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 163.316.913.1
Week 246.125.018.8
SecondaryPercentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Participants with >=20% Improvement38.046.353.0
Week 16: Participants with >=20% Improvement39.158.269.9
Week 24: Participants with >=20% Improvement42.459.768.7
Week 8: Participants with >=50% Improvement6.517.918.1
Week 16: Participants with >=50% Improvement17.437.326.5
Week 24: Participants with >=50% Improvement21.738.837.3
Week 8: Participants with >=70% Improvement3.311.94.8
Week 16: Participants with >=70% Improvement5.423.99.6
Week 24: Participants with >=70% Improvement8.720.915.7
Week 8: Participants with >=90% Improvement01.50
Week 16: Participants with >=90% Improvement1.102.4
Week 24: Participants with >=90% Improvement2.21.53.6
SecondaryPercentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 1618.673.373.9
Week 2423.079.078.3
SecondaryPercentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 168.255.153.8
Week 249.868.860.9
SecondaryPercentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 163.827.333.2
Week 242.745.544.6
SecondaryPercentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 166.038.640.8
Week 247.750.051.5
SecondaryChange From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-3.482 (-4.346 to -2.618)-11.151 (-12.028 to -10.274)-11.278 (-12.153 to -10.404)
Week 24-3.904 (-4.748 to -3.059)-11.407 (-12.265 to -10.549)-11.471 (-12.325 to -10.617)
SecondaryPercentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

Time frame:
Weeks 8, 16, 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 87.633.526.6
Week 1610.051.345.1
Week 2411.863.959.0
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

Time frame:
Weeks 8, 16, 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 830.171.269.7
Week 1636.479.579.6
Week 2437.883.386.8
SecondaryChange From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8-1.653 (-2.373 to -0.933)-6.818 (-7.549 to -6.086)-6.396 (-7.121 to -5.671)
Week 16-2.410 (-3.109 to -1.710)-8.545 (-9.255 to -7.835)-8.147 (-8.853 to -7.441)
Week 24-2.129 (-2.854 to -1.404)-8.954 (-9.691 to -8.218)-8.853 (-9.581 to -8.124)
SecondaryPercentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 1610.448.948.4
Week 2411.556.857.1
SecondaryPercentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 1613.156.854.3
Week 2415.365.360.9
SecondaryChange From Baseline in Modified vdH-S Erosion Score at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified vdH-S Erosion Score at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Modified vdH-S Erosion Score at Week 240.58 (0.33 to 0.83)0.36 (0.11 to 0.61)0.13 (-0.12 to 0.38)
SecondaryChange From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24

The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 240.37 (0.23 to 0.51)0.16 (0.02 to 0.30)0.16 (0.02 to 0.30)
SecondaryChange From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Hand Erosion Score0.40 ± 1.5550.18 ± 1.280-0.03 ± 1.514
Hand JSN Score0.26 ± 1.1060.10 ± 0.6370.08 ± 0.607
Hand Score0.66 ± 2.4410.28 ± 1.6490.05 ± 1.881
Foot Erosion Score0.14 ± 0.8010.15 ± 0.9820.14 ± 0.894
Foot JSN Score0.10 ± 0.5160.02 ± 0.5160.07 ± 0.632
Foot Score0.24 ± 1.1160.17 ± 1.1800.21 ± 1.210
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline64.763.567.3
Change of <=0.5 from Baseline72.174.478.0
SecondaryPercentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline66.866.371.4
Change of <=0.5 from Baseline72.976.880.2
SecondaryPercentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24

The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \<=0 (assessed by both readers) or \<=0.5 (assessed by at least one reader) was considered as no progression of JSN.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline78.678.880.1
Change of <=0.5 from Baseline85.588.188.3
SecondaryPercentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.18.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 2486.487.889.3
SecondaryPercentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24

Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 1.83.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 2484.089.089.9
SecondaryPercentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24

The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.11.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 2491.393.591.7
SecondaryPercentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24

Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Baseline4.53.63.7
Week 244.93.63.8
SecondaryChange From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 82.75 (1.98 to 3.52)4.83 (4.06 to 5.59)4.34 (3.56 to 5.1)
Week 163.03 (2.18 to 3.88)6.65 (5.80 to 7.49)5.93 (5.07 to 6.78)
Week 243.42 (2.53 to 4.32)7.39 (6.50 to 8.29)7.04 (6.14 to 7.94)
SecondaryChange From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 81.11 (0.12 to 2.09)2.28 (1.30 to 3.27)2.87 (1.89 to 3.86)
Week 161.96 (0.91 to 3.01)4.28 (3.24 to 5.33)3.41 (2.36 to 4.47)
Week 242.14 (1.07 to 3.22)4.17 (3.10 to 5.23)4.22 (3.14 to 5.29)
SecondaryChange From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline and Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Physical Function Score2.095 (1.251 to 2.940)3.879 (3.038 to 4.720)3.936 (3.090 to 4.782)
Week 16: Physical Function Score2.581 (1.669 to 3.492)6.124 (5.218 to 7.030)5.618 (4.704 to 6.532)
Week 24: Physical Function Score3.254 (2.310 to 4.197)6.703 (5.764 to 7.642)6.624 (5.680 to 7.567)
Week 8: Role-physical Score2.619 (1.828 to 3.410)3.599 (2.812 to 4.387)3.107 (2.315 to 3.899)
Week 16: Role-physical Score2.965 (2.120 to 3.810)5.616 (4.776 to 6.455)4.942 (4.095 to 5.789)
Week 24: Role-physical Score3.365 (2.477 to 4.253)6.549 (5.666 to 7.433)6.241 (5.354 to 7.129)
Week 8: Bodily Pain Score2.760 (1.974 to 3.546)5.456 (4.674 to 6.239)4.901 (4.115 to 5.688)
Week 16: Bodily Pain Score3.086 (2.196 to 3.977)7.485 (6.601 to 8.369)6.613 (5.721 to 7.505)
Week 24: Bodily Pain Score3.482 (2.556 to 4.408)7.811 (6.890 to 8.733)7.739 (6.813 to 8.664)
Week 8: General Health Score1.662 (0.906 to 2.418)4.111 (3.358 to 4.863)4.174 (3.418 to 4.931)
Week 16: General Health Score2.520 (1.681 to 3.358)5.719 (4.886 to 6.552)4.808 (3.967 to 5.648)
Week 24: General Health Score2.290 (1.415 to 3.165)5.794 (4.924 to 6.665)5.269 (4.394 to 6.144)
Week 8: Vitality Score2.505 (1.574 to 3.436)4.286 (3.358 to 5.213)4.669 (3.736 to 5.601)
Week 16: Vitality Score3.554 (2.559 to 4.548)6.967 (5.980 to 7.955)5.901 (4.904 to 6.898)
Week 24: Vitality Score3.835 (2.755 to 4.914)7.373 (6.299 to 8.447)7.009 (5.929 to 8.088)
Week 8: Social Function Score1.929 (0.976 to 2.882)3.337 (2.387 to 4.286)4.306 (3.352 to 5.260)
Week 16: Social Function Score2.884 (1.853 to 3.915)5.584 (4.560 to 6.609)5.022 (3.989 to 6.055)
Week 24: Social Function Score2.978 (1.964 to 3.992)5.806 (4.796 to 6.816)5.922 (4.909 to 6.936)
Week 8: Role-emotional Score1.108 (0.095 to 2.121)2.459 (1.451 to 3.468)2.294 (1.280 to 3.307)
Week 16: Role-emotional Score1.530 (0.499 to 2.562)4.497 (3.472 to 5.522)3.596 (2.563 to 4.630)
Week 24: Role-emotional Score1.813 (0.793 to 2.834)4.382 (3.367 to 5.398)4.255 (3.235 to 5.275)
Week 8: Mental Health Score1.081 (0.137 to 2.025)2.380 (1.440 to 3.320)3.048 (2.104 to 3.992)
Week 16: Mental Health Score2.195 (1.204 to 3.185)4.529 (3.546 to 5.513)3.896 (2.905 to 4.888)
Week 24: Mental Health Score2.335 (1.314 to 3.356)4.490 (3.474 to 5.506)4.767 (3.747 to 5.788)
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Week 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 826.433.127.3
Week 1631.742.331.8
Week 2430.937.534.3
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Week 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 837.845.241.2
Week 1635.859.351.0
Week 2440.260.155.9
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 82.451 (1.508 to 3.395)5.031 (4.092 to 5.970)4.850 (3.905 to 5.795)
Week 163.696 (2.675 to 4.717)6.977 (5.963 to 7.992)6.598 (5.574 to 7.622)
Week 243.559 (2.500 to 4.619)7.550 (6.496 to 8.603)7.111 (6.051 to 8.171)
SecondaryPercentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 845.956.051.8
Week 1650.460.956.7
Week 2445.560.559.6
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 166.477 (4.013 to 8.941)17.496 (15.049 to 19.943)14.646 (12.179 to 17.112)
Week 246.796 (4.298 to 9.294)18.371 (15.890 to 20.852)18.089 (15.596 to 20.581)
SecondaryChange From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 160.058 (0.043 to 0.074)0.112 (0.097 to 0.127)0.101 (0.086 to 0.116)
Week 240.053 (0.037 to 0.069)0.115 (0.099 to 0.131)0.116 (0.100 to 0.132)
SecondaryPercentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2434.066.866.2
Week 2848.371.272.0
Week 3668.877.778.7
Week 4469.779.776.7
Week 5268.779.175.9
SecondaryPercentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2415.232.834.3
Week 2822.741.440.5
Week 3639.344.145.7
Week 4443.848.348.7
Week 5243.751.349.1
SecondaryPercentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 244.619.313.7
Week 287.621.121.1
Week 3615.427.324.7
Week 4420.929.924.4
Week 5219.229.528.1
SecondaryACR Components at Weeks 24, 28, 36, 44 and 52

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
ACR Components at Weeks 24, 28, 36, 44 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Swollen Joint Count5.8 ± 6.993.4 ± 5.194.1 ± 5.77
Week 28: Swollen Joint Count4.1 ± 5.172.9 ± 4.953.2 ± 5.53
Week 36: Swollen Joint Count2.5 ± 3.772.4 ± 4.582.7 ± 4.67
Week 44: Swollen Joint Count2.1 ± 3.192.3 ± 4.422.8 ± 5.65
Week 52: Swollen Joint Count2.1 ± 3.592.1 ± 4.162.5 ± 4.83
Week 24: Tender Joint Count14.4 ± 13.169.1 ± 9.9410.5 ± 11.82
Week 28: Tender Joint Count11.7 ± 11.877.9 ± 9.028.6 ± 10.03
Week 36: Tender Joint Count8.5 ± 10.007.0 ± 8.727.5 ± 9.25
Week 44: Tender Joint Count7.5 ± 9.426.3 ± 8.457.0 ± 9.42
Week 52: Tender Joint Count7.4 ± 10.246.2 ± 8.187.3 ± 9.46
Week 24: Patient's Assessment of Pain5.21 ± 2.3683.77 ± 2.4573.70 ± 2.193
Week 28: Patient's Assessment of Pain4.66 ± 2.3413.50 ± 2.3113.45 ± 2.259
Week 36: Patient's Assessment of Pain3.78 ± 2.2973.28 ± 2.3363.20 ± 2.242
Week 44: Patient's Assessment of Pain3.67 ± 2.3123.22 ± 2.3703.24 ± 2.277
Week 52: Patient's Assessment of Pain3.53 ± 2.2533.10 ± 2.3333.21 ± 2.371
Week 24: PtGA of Disease Activity5.29 ± 2.3674.01 ± 2.5163.93 ± 2.276
Week 28: PtGA of Disease Activity4.75 ± 2.3383.76 ± 2.3483.62 ± 2.275
Week 36: PtGA of Disease Activity3.84 ± 2.2953.52 ± 2.3903.30 ± 2.318
Week 44: PtGA of Disease Activity3.78 ± 2.3783.36 ± 2.4473.50 ± 2.323
Week 52: PtGA of Disease Activity3.68 ± 2.3183.23 ± 2.3833.28 ± 2.354
Week 24: PGA of Disease Activity4.22 ± 2.3422.74 ± 2.1132.66 ± 1.906
Week 28: PGA of Disease Activity3.27 ± 1.9302.44 ± 1.9412.33 ± 1.668
Week 36: PGA of Disease Activity2.28 ± 1.5942.10 ± 1.7772.06 ± 1.716
Week 44: PGA of Disease Activity2.06 ± 1.6491.97 ± 1.8421.93 ± 1.631
Week 52: PGA of Disease Activity1.90 ± 1.6541.77 ± 1.6451.77 ± 1.616
Week 24: HAQ-DI score1.1350 ± 0.619840.8766 ± 0.598930.8194 ± 0.57287
Week 28: HAQ-DI score1.0457 ± 0.590510.8497 ± 0.618630.7985 ± 0.56677
Week 36: HAQ-DI score0.9621 ± 0.606950.8091 ± 0.615880.7376 ± 0.56257
Week 44: HAQ-DI score0.9117 ± 0.633530.7927 ± 0.599790.7804 ± 0.57721
Week 52: HAQ-DI score0.9069 ± 0.636950.7917 ± 0.595270.7364 ± 0.58655
Week 24: CRP1.543 ± 2.15720.961 ± 1.28680.790 ± 0.8390
Week 28: CRP1.120 ± 1.51400.956 ± 1.37490.885 ± 1.0299
Week 36: CRP0.920 ± 1.46740.892 ± 1.31090.837 ± 1.0730
Week 44: CRP0.858 ± 1.05580.812 ± 1.01390.992 ± 1.9875
Week 52: CRP0.907 ± 1.59850.937 ± 1.24220.910 ± 1.2756
SecondaryChange From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Swollen Joint Count-6.4 ± 7.25-8.2 ± 6.09-8.8 ± 5.50
Week 28: Swollen Joint Count-8.1 ± 6.99-8.8 ± 5.98-9.6 ± 6.65
Week 36: Swollen Joint Count-9.9 ± 6.47-9.2 ± 5.81-10.2 ± 6.76
Week 44: Swollen Joint Count-10.1 ± 6.77-9.3 ± 6.24-10.2 ± 6.28
Week 52: Swollen Joint Count-10.2 ± 6.79-9.6 ± 6.28-10.4 ± 6.17
Week 24: Tender Joint Count-7.0 ± 10.91-10.4 ± 9.51-11.9 ± 9.98
Week 28: Tender Joint Count-9.7 ± 10.78-11.7 ± 9.24-13.7 ± 10.53
Week 36: Tender Joint Count-13.2 ± 10.78-12.5 ± 9.68-14.6 ± 10.31
Week 44: Tender Joint Count-14.0 ± 11.02-13.3 ± 9.56-15.2 ± 10.25
Week 52: Tender Joint Count-14.1 ± 11.39-13.4 ± 10.03-15.0 ± 10.51
Week 24: Patient's Assessment of Pain-1.08 ± 2.441-2.55 ± 2.477-2.41 ± 2.335
Week 28: Patient's Assessment of Pain-1.63 ± 2.420-2.83 ± 2.519-2.66 ± 2.416
Week 36: Patient's Assessment of Pain-2.51 ± 2.588-3.02 ± 2.534-2.89 ± 2.540
Week 44: Patient's Assessment of Pain-2.62 ± 2.640-3.07 ± 2.644-2.87 ± 2.601
Week 52: Patient's Assessment of Pain-2.75 ± 2.659-3.20 ± 2.555-2.89 ± 2.681
Week 24: PtGA of Disease Activity-1.25 ± 2.601-2.52 ± 2.490-2.40 ± 2.383
Week 28: PtGA of Disease Activity-1.79 ± 2.543-2.79 ± 2.560-2.70 ± 2.382
Week 36: PtGA of Disease Activity-2.70 ± 2.555-2.99 ± 2.569-3.01 ± 2.445
Week 44: PtGA of Disease Activity-2.76 ± 2.741-3.15 ± 2.650-2.86 ± 2.559
Week 52: PtGA of Disease Activity-2.85 ± 2.757-3.29 ± 2.558-3.06 ± 2.527
Week 24: PGA of Disease Activity-2.45 ± 2.248-3.84 ± 2.316-3.93 ± 2.227
Week 28: PGA of Disease Activity-3.42 ± 2.189-4.16 ± 2.175-4.28 ± 2.054
Week 36: PGA of Disease Activity-4.39 ± 2.052-4.49 ± 2.116-4.53 ± 2.173
Week 44: PGA of Disease Activity-4.61 ± 2.043-4.55 ± 2.139-4.70 ± 2.084
Week 52: PGA of Disease Activity-4.77 ± 2.007-4.78 ± 1.996-4.81 ± 2.120
Week 24: HAQ-DI score-0.1646 ± 0.53253-0.4044 ± 0.54194-0.4257 ± 0.50337
Week 28: HAQ-DI score-0.2547 ± 0.50426-0.4383 ± 0.55648-0.4429 ± 0.51556
Week 36: HAQ-DI score-0.3423 ± 0.52951-0.4702 ± 0.55698-0.5000 ± 0.55438
Week 44: HAQ-DI score-0.3868 ± 0.57065-0.4824 ± 0.57091-0.4652 ± 0.56121
Week 52: HAQ-DI score-0.3848 ± 0.58049-0.4824 ± 0.56167-0.5082 ± 0.58255
Week 24: CRP-0.547 ± 2.5657-1.038 ± 2.0932-1.052 ± 2.1295
Week 28: CRP-0.993 ± 2.3669-1.028 ± 2.0476-0.976 ± 2.1663
Week 36: CRP-1.202 ± 2.3234-1.098 ± 2.1102-1.020 ± 2.1985
Week 44: CRP-1.262 ± 2.5377-1.145 ± 2.1378-0.861 ± 2.8133
Week 52: CRP-1.237 ± 2.8242-1.021 ± 2.2289-0.937 ± 2.4116
SecondaryPercent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52
percent changePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Swollen Joint Count-53.44 ± 45.655-72.06 ± 33.971-73.17 ± 30.614
Week 28: Swollen Joint Count-66.15 ± 37.305-78.02 ± 30.197-78.85 ± 28.109
Week 36: Swollen Joint Count-80.38 ± 28.144-82.82 ± 26.054-81.49 ± 27.338
Week 44: Swollen Joint Count-81.85 ± 26.328-82.10 ± 27.742-83.32 ± 24.289
Week 52: Swollen Joint Count-82.34 ± 30.494-83.18 ± 30.121-84.07 ± 24.070
Week 24: Tender Joint Count-32.53 ± 44.850-54.81 ± 37.134-57.11 ± 35.073
Week 28: Tender Joint Count-45.52 ± 41.132-62.48 ± 32.820-64.31 ± 31.767
Week 36: Tender Joint Count-62.21 ± 34.292-66.12 ± 32.829-68.50 ± 30.000
Week 44: Tender Joint Count-65.88 ± 33.344-70.90 ± 29.688-72.10 ± 27.670
Week 52: Tender Joint Count-67.29 ± 35.583-70.29 ± 31.985-69.82 ± 32.122
Week 24: Patient's Assessment of Pain-11.52 ± 48.647-38.44 ± 40.734-36.64 ± 38.086
Week 28: Patient's Assessment of Pain-22.20 ± 42.404-42.17 ± 41.660-41.02 ± 39.624
Week 36: Patient's Assessment of Pain-35.65 ± 43.207-45.89 ± 40.125-43.29 ± 44.442
Week 44: Patient's Assessment of Pain-37.45 ± 43.534-46.48 ± 41.725-43.60 ± 42.560
Week 52: Patient's Assessment of Pain-38.23 ± 47.430-49.00 ± 39.082-43.51 ± 45.742
Week 24: PtGA of Disease Activity-13.78 ± 45.943-37.18 ± 38.628-33.90 ± 51.672
Week 28: PtGA of Disease Activity-23.78 ± 40.895-39.92 ± 40.228-40.70 ± 36.587
Week 36: PtGA of Disease Activity-38.82 ± 37.114-44.21 ± 36.982-45.52 ± 38.659
Week 44: PtGA of Disease Activity-38.45 ± 43.993-46.64 ± 38.228-42.45 ± 39.243
Week 52: PtGA of Disease Activity-39.34 ± 44.933-48.73 ± 38.925-45.50 ± 40.653
Week 24: PGA of Disease Activity-36.13 ± 33.383-57.60 ± 32.634-59.06 ± 28.137
Week 28: PGA of Disease Activity-49.72 ± 30.129-62.89 ± 28.027-64.14 ± 25.784
Week 36: PGA of Disease Activity-64.57 ± 25.695-67.98 ± 25.989-67.74 ± 28.029
Week 44: PGA of Disease Activity-68.32 ± 25.560-69.79 ± 26.949-70.27 ± 24.516
Week 52: PGA of Disease Activity-71.05 ± 25.056-73.09 ± 24.133-72.46 ± 24.485
Week 24: HAQ-DI score-6.86 ± 54.753-25.47 ± 63.639-33.72 ± 51.766
Week 28: HAQ-DI score-15.66 ± 49.522-28.82 ± 73.930-33.91 ± 59.310
Week 36: HAQ-DI score-23.34 ± 46.393-31.95 ± 78.348-37.74 ± 56.329
Week 44: HAQ-DI score-27.01 ± 49.683-33.84 ± 60.164-32.45 ± 72.337
Week 52: HAQ-DI score-26.83 ± 54.380-33.49 ± 63.823-35.02 ± 65.765
Week 24: CRP19.81 ± 150.274-26.90 ± 110.466-28.35 ± 88.038
Week 28: CRP-0.80 ± 155.637-21.09 ± 144.28715.69 ± 468.613
Week 36: CRP-6.70 ± 183.299-25.47 ± 157.839-23.97 ± 104.641
Week 44: CRP-8.33 ± 143.843-37.54 ± 76.302-17.44 ± 127.594
Week 52: CRP-0.25 ± 208.267-23.15 ± 104.461-0.99 ± 193.429
SecondaryPercentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 2491.786.8
SecondaryPercentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 2487.279.2
SecondaryPercentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 2482.675.0
SecondaryChange From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-0.1646 ± 0.53253-0.4044 ± 0.54194-0.4257 ± 0.50337
Week 28-0.2547 ± 0.50426-0.4383 ± 0.55648-0.4429 ± 0.51556
Week 36-0.3423 ± 0.52951-0.4702 ± 0.55698-0.5000 ± 0.55438
Week 44-0.3868 ± 0.57065-0.4824 ± 0.57091-0.4652 ± 0.56121
Week 52-0.3848 ± 0.58049-0.4824 ± 0.56167-0.5082 ± 0.58255
SecondaryPercentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2434.152.558.3
Week 2842.458.463.4
Week 3648.458.261.9
Week 4450.960.061.4
Week 5250.560.962.9
SecondaryPercentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 2492.088.6
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2455.579.083.8
Week 2872.385.085.9
Week 3686.586.992.5
Week 4491.091.891.9
Week 5289.089.789.4
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 249.325.624.4
Week 2813.227.530.4
Week 3625.736.039.5
Week 4430.038.438.0
Week 5234.239.739.6
SecondaryChange From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.02 ± 1.101-1.63 ± 1.051-1.68 ± 0.976
Week 28-1.38 ± 1.099-1.78 ± 1.038-1.86 ± 1.066
Week 36-1.92 ± 1.086-1.97 ± 1.114-2.08 ± 1.088
Week 44-2.04 ± 1.098-2.09 ± 1.107-2.08 ± 1.063
Week 52-2.14 ± 1.142-2.08 ± 1.121-2.11 ± 1.128
SecondaryPercentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52

The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2446.676.472.8
Week 2864.679.383.1
Week 3678.782.384.3
Week 4477.683.782.2
Week 5281.286.382.9
SecondaryPercentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2432.657.645.5
Week 5267.365.560.0
SecondaryChange From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.1 ± 1.66-1.6 ± 1.75-1.6 ± 1.63
Week 52-2.1 ± 1.61-1.9 ± 1.65-2.0 ± 1.78
SecondaryPercentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2441.160.768.1
Week 5278.581.981.1
SecondaryChange From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-4.6 ± 7.88-6.1 ± 7.83-6.6 ± 7.84
Week 52-7.4 ± 9.18-7.3 ± 9.74-7.4 ± 8.59
SecondaryChange From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.399 ± 1.3169-2.496 ± 1.5024-2.506 ± 1.2578
Week 52-3.041 ± 1.4979-3.197 ± 1.5212-3.161 ± 1.4646
SecondaryPercentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 248.131.624.6
Week 5238.545.346.3
SecondaryChange From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.260 ± 1.4909-2.658 ± 1.6770-2.672 ± 1.4589
Week 52-3.085 ± 1.6277-3.271 ± 1.6453-3.267 ± 1.5646
SecondaryPercentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 247.629.527.6
Week 5234.943.243.0
SecondaryChange From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-16.377 ± 19.1814-24.718 ± 16.7967-26.578 ± 15.3393
Week 28-22.199 ± 17.9394-26.573 ± 15.5254-29.613 ± 17.6129
Week 36-29.251 ± 18.1137-28.889 ± 16.4372-31.782 ± 16.7698
Week 44-30.754 ± 18.5016-30.108 ± 16.6013-32.126 ± 15.7605
Week 52-31.209 ± 18.9981-30.512 ± 17.5074-32.282 ± 16.6320
SecondaryChange From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.34 ± 2.144-2.97 ± 2.382-3.32 ± 2.098
Week 52-3.75 ± 2.391-3.84 ± 2.449-4.10 ± 2.387
SecondaryPercentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2415.148.943.5
Week 5256.361.160.1
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52

MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 246.326.519.7
Week 5231.632.936.8
SecondaryPercentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52

A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 241.34.65.1
Week 526.917.112.2
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.374 ± 2.4269-2.652 ± 2.3825-2.674 ± 1.9941
Week 52-2.986 ± 2.4945-2.883 ± 2.5193-3.084 ± 2.1843
SecondaryPercentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Participants with >=20% Improvement44.062.573.1
Week 52: Participants with >=20% Improvement71.670.379.7
Week 24: Participants with >=50% Improvement22.040.639.7
Week 52: Participants with >=50% Improvement50.042.250.6
Week 24: Participants with >=70% Improvement8.821.916.7
Week 52: Participants with >=70% Improvement23.926.630.4
Week 24: Participants with >=90% Improvement2.21.63.8
Week 52: Participants with >=90% Improvement6.810.98.9
SecondaryChange From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-2.989 ± 6.1515-11.685 ± 12.3496-12.574 ± 11.8391
Week 52-11.016 ± 9.9801-11.977 ± 12.0847-12.857 ± 11.3052
SecondaryPercentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2439.894.893.8
Week 5295.997.198.3
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2423.380.881.8
Week 5288.488.891.9
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2410.270.363.6
Week 5276.777.181.5
SecondaryPercentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 242.846.546.6
Week 5255.254.761.3
SecondaryPercentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2411.458.159.7
Week 5259.673.569.9
SecondaryPercentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2415.366.963.6
Week 5270.979.476.3
SecondaryPercentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2419.972.171.0
Week 5284.377.184.4
SecondaryPercentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 248.051.252.8
Week 5266.960.066.5
SecondaryPercentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2412.165.661.4
Week 5256.868.668.7
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2440.785.490.3
Week 5284.892.289.4
SecondaryChange From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-2.142 ± 6.4593-8.901 ± 7.3657-9.249 ± 7.0988
Week 52-8.815 ± 7.2714-9.235 ± 7.3840-9.839 ± 6.8777
SecondaryChange From Baseline in Modified vdH-S Score at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified vdH-S Score at Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Modified vdH-S Score at Week 521.25 ± 3.5080.97 ± 3.6231.07 ± 3.843
SecondaryChange in Total Modified vdH-S Score From Week 24 to Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

Time frame:
From Week 24 to Week 52
Reported as:
Mean · units on a scale
Change in Total Modified vdH-S Score From Week 24 to Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Total Modified vdH-S Score From Week 24 to Week 520.25 ± 1.6350.23 ± 1.8080.62 ± 2.530
SecondaryChange From Baseline in Modified vdH-S Erosion Score at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified vdH-S Erosion Score at Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Modified vdH-S Erosion Score at Week 520.92 ± 2.4970.67 ± 2.7070.70 ± 2.631
SecondaryChange in Modified vdH-S Erosion Score From Week 24 to Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

Time frame:
From Week 24 to Week 52
Reported as:
Mean · units on a scale
Change in Modified vdH-S Erosion Score From Week 24 to Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-S Erosion Score From Week 24 to Week 520.17 ± 1.2770.10 ± 1.4220.39 ± 1.725
SecondaryChange From Baseline in Modified vdH-S JSN Score at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified vdH-S JSN Score at Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Modified vdH-S JSN Score at Week 520.33 ± 1.3560.29 ± 1.2720.38 ± 1.633
SecondaryChange in Modified vdH-S JSN Score From Week 24 to Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

Time frame:
From Week 24 to Week 52
Reported as:
Mean · units on a scale
Change in Modified vdH-S JSN Score From Week 24 to Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-S JSN Score From Week 24 to Week 520.07 ± 0.6350.13 ± 0.7050.23 ± 1.088
SecondaryChange From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Hand Erosion Score0.66 ± 1.8150.37 ± 1.9690.35 ± 1.830
Hand JSN Score0.29 ± 1.1810.19 ± 0.9130.22 ± 1.235
Hand Score0.95 ± 2.7060.56 ± 2.5890.57 ± 2.759
Foot Erosion Score0.26 ± 1.0140.30 ± 1.3390.34 ± 1.413
Foot JSN Score0.04 ± 0.3530.10 ± 0.6600.16 ± 0.864
Foot Score0.30 ± 1.2200.40 ± 1.6870.50 ± 1.939
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline57.455.756.8
Change of <=0.5 from Baseline67.467.272.1
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline58.359.660.3
Change of <=0.5 from Baseline70.471.172.1
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline78.775.379.5
Change of <=0.5 from Baseline88.386.086.5
SecondaryPercentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.39.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 5280.482.685.2
SecondaryPercentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52

Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 2.22.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 5282.284.387.3
SecondaryPercentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52

Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \<=SDC of 1.02.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 5291.391.590.4
SecondaryPercentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52

Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Baseline6.94.66.9
Week 527.85.17.0
SecondaryChange From Baseline in SF-36 PCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in SF-36 PCS Score at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 243.782 ± 7.17767.838 ± 8.03357.183 ± 6.9793
Week 528.124 ± 8.21929.511 ± 8.31768.960 ± 8.5891
SecondaryChange From Baseline in SF-36 MCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in SF-36 MCS Score at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 242.211 ± 10.13684.452 ± 9.95604.128 ± 9.1814
Week 524.297 ± 10.89604.465 ± 9.77804.076 ± 9.1101
SecondaryChange From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Physical Function Score3.602 ± 7.73887.052 ± 8.50206.772 ± 7.5920
Week 52: Physical Function Score7.722 ± 8.94808.489 ± 8.85998.374 ± 8.7884
Week 24: Role-physical Score3.695 ± 7.59506.897 ± 7.72406.381 ± 7.2203
Week 52: Role-physical Score6.560 ± 8.53997.677 ± 8.29957.344 ± 7.7145
Week 24: Bodily Pain Score3.882 ± 8.30098.333 ± 8.38527.833 ± 7.3390
Week 52: Bodily Pain Score8.460 ± 8.465910.238 ± 8.71859.457 ± 9.7977
Week 24: General Health Score2.255 ± 7.21765.963 ± 7.87945.067 ± 7.4182
Week 52: General Health Score6.396 ± 8.55897.173 ± 7.27036.366 ± 8.4199
Week 24: Vitality Score4.224 ± 9.08787.914 ± 9.46386.970 ± 9.4889
Week 52: Vitality Score7.879 ± 9.41608.646 ± 9.51317.654 ± 9.3905
Week 24: Social Function Score3.088 ± 10.43306.551 ± 9.70765.892 ± 8.5510
Week 52: Social Function Score6.278 ± 10.94447.199 ± 10.13156.787 ± 9.5326
Week 24: Role-emotional Score1.910 ± 10.07724.535 ± 10.13044.107 ± 8.9473
Week 52: Role-emotional Score4.057 ± 10.87954.970 ± 10.16854.607 ± 8.7627
Week 24: Mental Health Score2.583 ± 9.22224.605 ± 9.79054.752 ± 8.9336
Week 52: Mental Health Score5.153 ± 10.07244.829 ± 9.36654.741 ± 9.3825
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2442.263.458.5
Week 5263.067.165.5
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2432.540.336.8
Week 5241.744.938.9
SecondaryChange From Baseline in FACIT-Fatigue Score at Weeks 24 and 52

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 243.844 ± 9.04408.034 ± 9.88886.970 ± 8.6274
Week 527.548 ± 9.37458.927 ± 9.46467.686 ± 9.0833
SecondaryPercentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2449.463.962.8
Week 5268.369.768.6
SecondaryChange From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 248.456 ± 25.720419.282 ± 23.522017.500 ± 22.6981
Week 5221.474 ± 25.597423.295 ± 23.627019.983 ± 24.7643
SecondaryChange From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 240.060 ± 0.15580.124 ± 0.14760.117 ± 0.1307
Week 520.137 ± 0.16050.146 ± 0.15870.135 ± 0.1469
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-5.64 ± 28.355-3.77 ± 28.029-1.20 ± 17.127
Week 52-5.37 ± 25.365-4.47 ± 20.454-1.74 ± 17.084
SecondaryChange From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-12.14 ± 29.027-21.28 ± 25.621-20.08 ± 22.084
Week 52-21.27 ± 31.502-27.93 ± 25.263-22.10 ± 26.172
SecondaryChange From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-13.42 ± 29.916-21.68 ± 27.065-20.90 ± 22.814
Week 52-22.06 ± 32.092-28.19 ± 25.536-22.24 ± 26.920
SecondaryChange From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-10.80 ± 26.131-23.03 ± 25.559-21.07 ± 21.493
Week 52-24.13 ± 27.436-27.14 ± 25.657-26.11 ± 25.361
SecondaryPercentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5268.778.977.0
Week 6877.085.280.7
Week 7675.683.182.5
Week 8480.185.180.6
Week 10079.282.184.9
SecondaryPercentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5244.350.949.6
Week 6849.560.858.6
Week 7650.956.058.3
Week 8456.363.857.8
Week 10055.260.762.3
SecondaryPercentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5219.529.728.3
Week 6827.835.536.1
Week 7627.936.432.7
Week 8429.642.839.4
Week 10034.339.338.6
SecondaryACR Components at Weeks 52, 68, 76, 84 and 100

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Mean · units on a scale
ACR Components at Weeks 52, 68, 76, 84 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Swollen Joint Count2.1 ± 3.582.1 ± 4.182.5 ± 4.83
Week 68: Swollen Joint Count1.6 ± 3.101.7 ± 3.872.0 ± 3.79
Week 76: Swollen Joint Count1.6 ± 3.171.8 ± 3.722.3 ± 4.59
Week 84: Swollen Joint Count1.6 ± 3.021.6 ± 3.822.0 ± 5.01
Week 100: Swollen Joint Count1.8 ± 3.751.6 ± 3.992.0 ± 4.11
Week 52: Tender Joint Count7.4 ± 10.306.3 ± 8.207.2 ± 9.49
Week 68: Tender Joint Count6.0 ± 8.835.0 ± 6.836.3 ± 9.27
Week 76: Tender Joint Count5.7 ± 8.315.2 ± 7.186.2 ± 8.90
Week 84: Tender Joint Count5.1 ± 7.324.7 ± 7.205.9 ± 9.22
Week 100: Tender Joint Count5.5 ± 8.444.7 ± 6.806.0 ± 8.90
Week 52: Patient's Assessment of Pain3.53 ± 2.2673.12 ± 2.3353.17 ± 2.343
Week 68: Patient's Assessment of Pain3.26 ± 2.3132.68 ± 2.2402.64 ± 2.105
Week 76: Patient's Assessment of Pain3.17 ± 2.2712.73 ± 2.2172.70 ± 2.115
Week 84: Patient's Assessment of Pain2.97 ± 2.1502.67 ± 2.1812.65 ± 2.217
Week 100: Patient's Assessment of Pain2.90 ± 2.2212.59 ± 2.2902.57 ± 2.138
Week 52: PtGA of Disease Activity3.68 ± 2.3313.25 ± 2.3803.24 ± 2.322
Week 68: PtGA of Disease Activity3.50 ± 2.3552.95 ± 2.2822.85 ± 2.213
Week 76: PtGA of Disease Activity3.25 ± 2.3562.90 ± 2.2732.95 ± 2.222
Week 84: PtGA of Disease Activity3.09 ± 2.2732.88 ± 2.2522.83 ± 2.222
Week 100: PtGA of Disease Activity3.15 ± 2.3952.85 ± 2.3782.60 ± 2.165
Week 52: PGA of Disease Activity1.89 ± 1.6541.78 ± 1.6471.77 ± 1.617
Week 68: PGA of Disease Activity1.63 ± 1.5141.56 ± 1.5381.61 ± 1.466
Week 76: PGA of Disease Activity1.45 ± 1.4691.67 ± 1.6601.57 ± 1.524
Week 84: PGA of Disease Activity1.55 ± 1.4921.51 ± 1.6191.50 ± 1.558
Week 100: PGA of Disease Activity1.39 ± 1.5101.49 ± 1.5811.41 ± 1.405
Week 52: HAQ-DI score0.9073 ± 0.638120.7942 ± 0.597110.7317 ± 0.58430
Week 68: HAQ-DI score0.8425 ± 0.617570.7625 ± 0.595240.6836 ± 0.56049
Week 76: HAQ-DI score0.8311 ± 0.621010.6978 ± 0.565880.6996 ± 0.55988
Week 84: HAQ-DI score0.8076 ± 0.624650.7134 ± 0.595280.6775 ± 0.58870
Week 100: HAQ-DI score0.7692 ± 0.599600.6747 ± 0.572130.6420 ± 0.56838
Week 52: CRP0.904 ± 1.60390.930 ± 1.24430.886 ± 1.2366
Week 68: CRP0.861 ± 1.15860.884 ± 1.35200.796 ± 1.1109
Week 76: CRP0.903 ± 1.46240.882 ± 1.25040.839 ± 1.1693
Week 84: CRP0.898 ± 1.32290.856 ± 1.19260.872 ± 1.3239
Week 100: CRP0.880 ± 1.34150.826 ± 1.22770.820 ± 1.1227
SecondaryChange From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame:
Baseline, Weeks 52, 68, 76, 84 and 100
Reported as:
Mean · units on a scale
Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Swollen Joint Count-10.2 ± 6.72-9.6 ± 6.30-10.4 ± 6.16
Week 68: Swollen Joint Count-10.7 ± 6.76-10.0 ± 6.50-10.9 ± 7.22
Week 76: Swollen Joint Count-10.7 ± 5.98-10.0 ± 6.33-10.7 ± 6.18
Week 84: Swollen Joint Count-10.6 ± 6.06-10.1 ± 6.34-10.7 ± 7.08
Week 100: Swollen Joint Count-10.6 ± 6.15-10.2 ± 6.88-10.8 ± 6.66
Week 52: Tender Joint Count-14.1 ± 11.38-13.5 ± 10.04-15.2 ± 10.45
Week 68: Tender Joint Count-15.7 ± 10.94-14.8 ± 10.15-16.0 ± 11.02
Week 76: Tender Joint Count-16.1 ± 10.97-14.7 ± 10.22-16.1 ± 10.91
Week 84: Tender Joint Count-16.6 ± 11.33-15.3 ± 10.50-16.0 ± 11.22
Week 100: Tender Joint Count-16.3 ± 11.27-15.3 ± 11.10-16.4 ± 10.70
Week 52: Patient's Assessment of Pain-2.78 ± 2.645-3.20 ± 2.557-2.92 ± 2.686
Week 68: Patient's Assessment of Pain-3.10 ± 2.707-3.62 ± 2.530-3.46 ± 2.574
Week 76: Patient's Assessment of Pain-3.18 ± 2.724-3.57 ± 2.566-3.38 ± 2.620
Week 84: Patient's Assessment of Pain-3.35 ± 2.595-3.64 ± 2.568-3.42 ± 2.669
Week 100: Patient's Assessment of Pain-3.41 ± 2.578-3.69 ± 2.625-3.52 ± 2.615
Week 52: PtGA of Disease Activity-2.87 ± 2.761-3.29 ± 2.553-3.09 ± 2.523
Week 68: PtGA of Disease Activity-3.08 ± 2.786-3.58 ± 2.446-3.49 ± 2.500
Week 76: PtGA of Disease Activity-3.32 ± 2.860-3.63 ± 2.512-3.38 ± 2.501
Week 84: PtGA of Disease Activity-3.46 ± 2.752-3.67 ± 2.572-3.50 ± 2.579
Week 100: PtGA of Disease Activity-3.40 ± 2.846-3.67 ± 2.612-3.73 ± 2.493
Week 52: PGA of Disease Activity-4.79 ± 1.992-4.77 ± 2.001-4.82 ± 2.117
Week 68: PGA of Disease Activity-5.06 ± 2.037-4.98 ± 1.992-5.01 ± 2.105
Week 76: PGA of Disease Activity-5.23 ± 1.995-4.86 ± 2.044-5.03 ± 2.078
Week 84: PGA of Disease Activity-5.13 ± 2.040-5.06 ± 2.074-5.09 ± 2.142
Week 100: PGA of Disease Activity-5.26 ± 2.098-5.05 ± 2.011-5.18 ± 2.044
Week 52: HAQ-DI score-0.3899 ± 0.58250-0.4801 ± 0.56246-0.5111 ± 0.58347
Week 68: HAQ-DI score-0.4668 ± 0.59226-0.5120 ± 0.54928-0.5631 ± 0.54528
Week 76: HAQ-DI score-0.4740 ± 0.57852-0.5694 ± 0.56421-0.5448 ± 0.54739
Week 84: HAQ-DI score-0.5041 ± 0.59716-0.5653 ± 0.59488-0.5656 ± 0.57921
Week 100: HAQ-DI score-0.5356 ± 0.56707-0.5859 ± 0.58199-0.6000 ± 0.56858
Week 52: CRP-1.262 ± 2.8315-1.021 ± 2.2301-0.959 ± 2.4188
Week 68: CRP-1.212 ± 2.3061-1.081 ± 2.1585-1.060 ± 2.3334
Week 76: CRP-1.283 ± 2.8163-1.098 ± 2.3654-1.017 ± 2.2801
Week 84: CRP-1.230 ± 2.4262-1.101 ± 2.1216-0.940 ± 2.3781
Week 100: CRP-1.244 ± 2.5828-1.129 ± 2.2261-1.042 ± 2.0600
SecondaryPercent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame:
Baseline, Weeks 52, 68, 76, 84 and 100
Reported as:
Mean · percent change
Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100
percent changePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Swollen Joint Count-82.64 ± 30.161-83.03 ± 30.210-84.27 ± 23.698
Week 68: Swollen Joint Count-87.41 ± 24.049-86.08 ± 29.764-86.41 ± 22.642
Week 76: Swollen Joint Count-87.98 ± 20.617-86.05 ± 21.096-85.82 ± 22.291
Week 84: Swollen Joint Count-87.72 ± 22.243-87.68 ± 23.304-87.16 ± 24.888
Week 100: Swollen Joint Count-87.61 ± 21.214-86.19 ± 40.865-86.31 ± 24.106
Week 52: Tender Joint Count-67.29 ± 35.725-70.18 ± 32.062-70.54 ± 31.311
Week 68: Tender Joint Count-74.28 ± 29.764-75.63 ± 29.437-74.40 ± 29.760
Week 76: Tender Joint Count-75.71 ± 27.653-74.71 ± 29.728-75.11 ± 28.559
Week 84: Tender Joint Count-77.21 ± 27.045-78.01 ± 26.112-75.45 ± 32.489
Week 100: Tender Joint Count-77.04 ± 27.510-75.96 ± 32.600-76.21 ± 27.345
Week 52: Patient's Assessment of Pain-39.52 ± 44.939-48.81 ± 39.191-43.86 ± 45.891
Week 68: Patient's Assessment of Pain-44.91 ± 44.371-55.77 ± 38.780-52.43 ± 41.186
Week 76: Patient's Assessment of Pain-46.02 ± 44.989-54.38 ± 39.135-51.34 ± 41.903
Week 84: Patient's Assessment of Pain-49.64 ± 40.991-55.28 ± 40.388-52.59 ± 43.131
Week 100: Patient's Assessment of Pain-50.82 ± 42.970-56.36 ± 41.310-54.27 ± 40.819
Week 52: PtGA of Disease Activity-39.70 ± 44.981-48.48 ± 38.982-46.07 ± 40.614
Week 68: PtGA of Disease Activity-42.93 ± 44.220-53.84 ± 35.096-52.47 ± 38.155
Week 76: PtGA of Disease Activity-46.42 ± 45.106-54.41 ± 35.276-50.66 ± 40.992
Week 84: PtGA of Disease Activity-49.38 ± 42.315-54.17 ± 37.132-51.86 ± 44.532
Week 100: PtGA of Disease Activity-48.17 ± 44.804-55.08 ± 37.052-57.09 ± 34.970
Week 52: PGA of Disease Activity-71.24 ± 24.771-72.95 ± 24.168-72.58 ± 24.579
Week 68: PGA of Disease Activity-74.76 ± 23.290-76.00 ± 22.550-74.48 ± 26.280
Week 76: PGA of Disease Activity-77.68 ± 23.015-74.42 ± 25.014-75.56 ± 23.613
Week 84: PGA of Disease Activity-75.77 ± 23.674-76.77 ± 24.433-76.49 ± 24.355
Week 100: PGA of Disease Activity-78.11 ± 24.049-77.15 ± 23.217-77.82 ± 22.733
Week 52: HAQ-DI score-27.27 ± 54.587-33.28 ± 64.067-35.17 ± 66.105
Week 68: HAQ-DI score-33.34 ± 49.027-37.47 ± 57.370-44.33 ± 44.064
Week 76: HAQ-DI score-34.38 ± 47.311-40.08 ± 58.932-41.84 ± 47.877
Week 84: HAQ-DI score-36.73 ± 47.541-40.10 ± 58.703-43.18 ± 52.116
Week 100: HAQ-DI score-40.36 ± 44.407-42.84 ± 54.187-47.54 ± 47.265
Week 52: CRP-2.67 ± 205.761-23.41 ± 104.622-1.34 ± 194.673
Week 68: CRP-1.68 ± 330.574-28.38 ± 138.159-13.91 ± 174.522
Week 76: CRP-10.76 ± 226.3327.85 ± 502.170-24.22 ± 110.486
Week 84: CRP-0.72 ± 387.986-26.87 ± 114.471-19.89 ± 131.695
Week 100: CRP-4.33 ± 196.246-23.99 ± 150.816-14.35 ± 171.666
SecondaryPercentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 5294.690.493.0
SecondaryPercentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 5281.381.983.8
SecondaryPercentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 5265.180.971.9
SecondaryChange From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline, Weeks 52, 68, 76, 84 and 100
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-0.3899 ± 0.58250-0.4801 ± 0.56246-0.5111 ± 0.58347
Week 68-0.4668 ± 0.59226-0.5120 ± 0.54928-0.5631 ± 0.54528
Week 76-0.4740 ± 0.57852-0.5694 ± 0.56421-0.5448 ± 0.54739
Week 84-0.5041 ± 0.59716-0.5653 ± 0.59488-0.5656 ± 0.57921
Week 100-0.5356 ± 0.56707-0.5859 ± 0.58199-0.6000 ± 0.56858
SecondaryPercentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5251.160.663.3
Week 6857.264.969.4
Week 7659.368.464.7
Week 8458.966.865.5
Week 10063.370.770.1
SecondaryPercentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 5291.690.488.5
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5289.389.790.2
Week 6892.792.592.7
Week 7694.190.293.3
Week 8494.892.792.5
Week 10094.390.692.7
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5234.739.740.4
Week 6839.044.949.1
Week 7643.244.243.5
Week 8441.850.948.1
Week 10042.447.551.6
SecondaryChange From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame:
Baseline, Weeks 52, 68, 76, 84 and 100
Reported as:
Mean · units on a scale
Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-2.14 ± 1.142-2.08 ± 1.124-2.14 ± 1.118
Week 68-2.29 ± 1.132-2.25 ± 1.170-2.30 ± 1.143
Week 76-2.35 ± 1.110-2.24 ± 1.147-2.24 ± 1.087
Week 84-2.40 ± 1.087-2.35 ± 1.181-2.31 ± 1.156
Week 100-2.42 ± 1.144-2.37 ± 1.215-2.36 ± 1.120
SecondaryPercentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100

The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5281.486.283.6
Week 6884.389.987.6
Week 7684.688.890.6
Week 8487.487.787.6
Week 10086.389.388.6
SecondaryPercentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame:
Weeks 52, 76, and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5267.366.061.0
Week 7672.371.867.5
Week 10075.277.567.7
SecondaryChange From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-2.1 ± 1.59-1.9 ± 1.66-2.1 ± 1.72
Week 76-2.3 ± 1.52-2.1 ± 1.66-2.2 ± 1.69
Week 100-2.4 ± 1.70-2.1 ± 1.65-2.2 ± 1.80
SecondaryPercentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5278.381.780.7
Week 7680.284.082.4
Week 10083.791.182.9
SecondaryChange From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-7.4 ± 9.22-7.3 ± 9.78-7.4 ± 8.66
Week 76-8.0 ± 9.55-7.8 ± 10.24-7.6 ± 8.93
Week 100-8.1 ± 9.63-7.9 ± 10.12-7.9 ± 9.14
SecondaryChange From Baseline in PASDAS Score at Weeks 52, 76 and 100

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in PASDAS Score at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-3.054 ± 1.4954-3.189 ± 1.5216-3.184 ± 1.4576
Week 76-3.503 ± 1.4708-3.418 ± 1.5646-3.436 ± 1.4428
Week 100-3.574 ± 1.4785-3.586 ± 1.5425-3.549 ± 1.4635
SecondaryPercentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \<= 3.2; Very low: PASDAS \<= 1.9.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Low39.044.846.7
Week 52: Very Low13.022.016.0
Week 76: Low52.150.049.8
Week 76: Very Low18.323.422.0
Week 100: Low55.354.757.8
Week 100: Very Low19.926.023.4
SecondaryChange From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-3.105 ± 1.6208-3.266 ± 1.6443-3.298 ± 1.5457
Week 76-3.499 ± 1.6303-3.528 ± 1.5778-3.541 ± 1.5048
Week 100-3.561 ± 1.6389-3.656 ± 1.6071-3.664 ± 1.5205
SecondaryPercentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5235.442.743.8
Week 7645.748.949.8
Week 10048.151.154.5
SecondaryChange From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame:
Baseline, Weeks 52, 68, 76, 84 and 100
Reported as:
Mean · units on a scale
Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-31.274 ± 18.8900-30.604 ± 17.5366-32.563 ± 16.4765
Week 68-33.918 ± 18.0463-33.146 ± 18.1727-34.900 ± 17.5749
Week 76-34.391 ± 17.4074-33.062 ± 17.5186-34.590 ± 16.5401
Week 84-35.240 ± 17.7891-33.622 ± 18.0612-34.570 ± 18.2685
Week 100-34.819 ± 17.9807-34.019 ± 19.2678-35.549 ± 16.5533
SecondaryPercentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\<=14; Remission: DAPSA\<=4.

Time frame:
Weeks 52, 68, 76, 84 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Low Disease Activity50.755.255.6
Week 52: Remission10.219.417.3
Week 68: Low Disease Activity54.164.363.3
Week 68: Remission15.623.823.9
Week 76: Low Disease Activity58.261.261.4
Week 76: Remission16.426.819.7
Week 84: Low Disease Activity60.666.564.6
Week 84: Remission17.828.023.6
Week 100: Low Disease Activity61.965.968.9
Week 100: Remission18.626.923.7
SecondaryChange From Baseline in mCPDAI Score at Weeks 52, 76 and 100

The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-3.78 ± 2.392-3.83 ± 2.458-4.14 ± 2.358
Week 76-4.39 ± 2.425-4.16 ± 2.539-4.47 ± 2.347
Week 100-4.44 ± 2.484-4.38 ± 2.433-4.52 ± 2.519
SecondaryPercentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100

The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5256.661.260.6
Week 7664.363.768.6
Week 10067.571.768.0
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100

MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5232.032.837.2
Week 7634.740.039.0
Week 10042.544.642.7
SecondaryPercentage of Participants With VLDA at Weeks 52, 76 and 100

A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With VLDA at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 527.016.812.4
Week 7612.219.614.8
Week 10014.618.815.0
SecondaryChange From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-2.986 ± 2.4945-2.923 ± 2.5194-3.084 ± 2.1843
Week 76-3.311 ± 2.6106-3.377 ± 2.5969-3.129 ± 2.1122
Week 100-3.718 ± 2.3960-3.472 ± 2.5233-3.330 ± 2.1598
SecondaryPercentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Participants with >=20% Improvement71.669.879.7
Week 76: Participants with >=20% Improvement74.182.081.8
Week 100: Participants with >=20% Improvement87.877.082.9
Week 52: Participants with >=50% Improvement50.042.950.6
Week 76: Participants with >=50% Improvement52.952.550.6
Week 100: Participants with >=50% Improvement59.857.455.3
Week 52: Participants with >=70% Improvement23.927.030.4
Week 76: Participants with >=70% Improvement31.831.126.0
Week 100: Participants with >=70% Improvement32.939.332.9
Week 52: Participants with >=90% Improvement6.811.18.9
Week 76: Participants with >=90% Improvement11.813.17.8
Week 100: Participants with >=90% Improvement18.311.59.2
SecondaryChange From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-11.030 ± 10.0077-11.991 ± 12.1194-12.875 ± 11.2905
Week 76-11.313 ± 10.0631-11.991 ± 12.2656-13.242 ± 11.8845
Week 100-11.089 ± 10.0239-12.101 ± 12.1322-13.274 ± 11.9673
SecondaryPercentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5295.997.098.3
Week 7697.696.497.1
Week 10095.697.098.2
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5288.388.891.9
Week 7692.887.993.0
Week 10091.987.889.4
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5276.676.981.5
Week 7685.575.880.2
Week 10087.575.080.0
SecondaryPercentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5255.054.460.7
Week 7665.159.468.0
Week 10069.457.364.1
SecondaryPercentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5259.473.470.5
Week 7671.175.876.7
Week 10073.076.177.5
SecondaryPercentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5270.879.376.9
Week 7678.379.482.6
Week 10078.881.178.8
SecondaryPercentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). IGA Response is defined as achieving IGA score of 0 or 1, and \>=2 grade reduction from baseline.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5284.276.984.4
Week 7685.577.686.0
Week 10088.176.482.4
SecondaryPercentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5266.759.865.9
Week 7672.964.272.1
Week 10076.958.867.1
SecondaryPercentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5256.568.468.5
Week 7666.966.768.9
Week 10074.769.664.8
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5284.892.289.4
Week 7691.989.090.1
Week 10091.794.488.5
SecondaryChange From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-8.855 ± 7.2738-9.272 ± 7.3903-9.873 ± 6.8832
Week 76-10.090 ± 7.0888-9.180 ± 7.2977-9.610 ± 7.0383
Week 100-10.130 ± 7.2798-9.291 ± 7.2851-9.635 ± 7.0884
SecondaryChange in Modified vdH-S Score From Baseline to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline to Week 100
Reported as:
Mean · units on a scale
Change in Modified vdH-S Score From Baseline to Week 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-S Score From Baseline to Week 1001.49 ± 6.8591.50 ± 4.3931.68 ± 7.018
SecondaryChange in Total Modified vdH-S Score From Week 52 to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.

Time frame:
From Week 52 to Week 100
Reported as:
Mean · units on a scale
Change in Total Modified vdH-S Score From Week 52 to Week 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Total Modified vdH-S Score From Week 52 to Week 1000.13 ± 3.7420.46 ± 2.4190.75 ± 4.021
SecondaryChange in Modified vdH-s Erosion Score From Baseline to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline to Week 100
Reported as:
Mean · units on a scale
Change in Modified vdH-s Erosion Score From Baseline to Week 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-s Erosion Score From Baseline to Week 1001.01 ± 4.0341.01 ± 3.3551.02 ± 4.676
SecondaryChange in Modified vdH-s Erosion Score From Week 52 to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
From Week 52 to Week 100
Reported as:
Mean · units on a scale
Change in Modified vdH-s Erosion Score From Week 52 to Week 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-s Erosion Score From Week 52 to Week 1000.09 ± 1.9780.26 ± 1.7510.45 ± 2.900
SecondaryChange in Modified vdH-s JSN Score From Baseline to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline to Week 100
Reported as:
Mean · units on a scale
Change in Modified vdH-s JSN Score From Baseline to Week 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-s JSN Score From Baseline to Week 1000.49 ± 2.9840.50 ± 1.3870.66 ± 2.722
SecondaryChange in Modified vdH-s JSN Score From Week 52 to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
From Week 52 to Week 100
Reported as:
Mean · units on a scale
Change in Modified vdH-s JSN Score From Week 52 to Week 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change in Modified vdH-s JSN Score From Week 52 to Week 1000.04 ± 1.9040.20 ± 0.9170.30 ± 1.319
SecondaryChange From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

Time frame:
Baseline to Week 100
Reported as:
Mean · units on a scale
Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Hand Erosion Score0.67 ± 2.9170.67 ± 2.8070.49 ± 3.007
Hand JSN Score0.35 ± 2.4430.34 ± 1.2470.32 ± 1.845
Hand Score1.02 ± 5.2441.02 ± 3.8150.81 ± 4.532
Foot Erosion Score0.34 ± 1.5960.33 ± 1.3620.53 ± 2.436
Foot JSN Score0.13 ± 0.9120.15 ± 0.6520.34 ± 1.608
Foot Score0.48 ± 2.3730.48 ± 1.6520.87 ± 3.761
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline60.855.662.6
Change of <=0.5 from Baseline72.163.972.5
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline64.261.165.4
Change of <=0.5 from Baseline75.073.175.4
SecondaryPercentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change of <=0 from Baseline77.568.573.9
Change of <=0.5 from Baseline84.379.681.0
SecondaryPercentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 3.46.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 10086.884.787.2
SecondaryPercentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100

Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \<=SDC of 2.66.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 10086.887.088.6
SecondaryPercentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100

Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.66.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 10090.789.488.2
SecondaryPercentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100

Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

Time frame:
Baseline, Weeks 24, 52, and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Baseline3.73.93.6
Week 243.73.94.1
Week 524.24.43.6
Week 1004.94.63.8
SecondaryChange From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 528.170 ± 8.21959.438 ± 8.28549.023 ± 8.6263
Week 769.762 ± 8.590810.814 ± 9.02909.707 ± 8.5010
Week 10010.508 ± 8.681911.282 ± 9.275310.559 ± 8.7449
SecondaryChange From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 524.383 ± 10.94024.540 ± 9.78484.127 ± 9.1368
Week 764.838 ± 11.05265.034 ± 10.03345.194 ± 9.4899
Week 1004.610 ± 11.25274.718 ± 9.90144.936 ± 9.5935
SecondaryChange From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52: Physical Function Score7.757 ± 8.97278.406 ± 8.84078.493 ± 8.7691
Week 76: Physical Function Score8.824 ± 9.66489.807 ± 9.50449.294 ± 8.2020
Week 100: Physical Function Score9.738 ± 9.840510.953 ± 9.776110.126 ± 8.9271
Week 52: Role-physical Score6.538 ± 8.51517.665 ± 8.29257.372 ± 7.7581
Week 76: Role-physical Score8.372 ± 8.72029.171 ± 8.58448.579 ± 7.6709
Week 100: Role-physical Score9.181 ± 8.65969.342 ± 9.17468.921 ± 8.1775
Week 52: Bodily Pain Score8.536 ± 8.460210.201 ± 8.73129.525 ± 9.8357
Week 76: Bodily Pain Score10.368 ± 9.105811.552 ± 9.859110.300 ± 9.0504
Week 100: Bodily Pain Score10.696 ± 9.385411.585 ± 10.352710.998 ± 8.9230
Week 52: General Health Score6.533 ± 8.52457.097 ± 7.25006.450 ± 8.4316
Week 76: General Health Score7.203 ± 8.33727.470 ± 7.61196.761 ± 7.9631
Week 100: General Health Score6.710 ± 8.72657.066 ± 7.58297.132 ± 8.4887
Week 52: Vitality Score7.997 ± 9.38788.695 ± 9.50337.637 ± 9.4393
Week 76: Vitality Score8.859 ± 9.43729.388 ± 9.86188.659 ± 9.6026
Week 100: Vitality Score9.648 ± 9.47789.827 ± 9.93489.155 ± 9.3569
Week 52: Social Function Score6.361 ± 10.99277.304 ± 10.10036.810 ± 9.5118
Week 76: Social Function Score7.509 ± 10.42498.623 ± 9.51767.914 ± 9.5191
Week 100: Social Function Score7.825 ± 10.85588.080 ± 9.53838.113 ± 9.4847
Week 52: Role-emotional Score4.111 ± 10.94134.998 ± 10.19644.699 ± 8.7759
Week 76: Role-emotional Score5.199 ± 11.18755.757 ± 10.07375.433 ± 9.2389
Week 100: Role-emotional Score4.784 ± 11.94825.720 ± 10.19915.128 ± 9.7998
Week 52: Mental Health Score5.209 ± 10.09584.826 ± 9.40384.839 ± 9.4029
Week 76: Mental Health Score5.481 ± 10.59275.430 ± 10.08026.124 ± 8.7930
Week 100: Mental Health Score5.514 ± 10.62045.477 ± 10.12026.148 ± 8.8743
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5263.466.865.9
Week 7670.673.865.5
Week 10072.470.168.6
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5242.345.338.9
Week 7643.944.443.5
Week 10042.146.443.6
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 527.692 ± 9.30718.935 ± 9.50337.699 ± 9.1417
Week 769.167 ± 9.04559.596 ± 10.47888.632 ± 8.8429
Week 1009.435 ± 9.451310.107 ± 10.20769.127 ± 8.9948
SecondaryPercentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Weeks 52, 76 and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100
percentage of participantsPlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5268.769.468.1
Week 7670.669.374.4
Week 10072.072.874.1
SecondaryChange From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 5221.608 ± 25.599223.392 ± 23.699020.190 ± 24.8348
Week 7624.176 ± 27.720525.053 ± 26.037222.251 ± 24.6934
Week 10025.901 ± 28.402827.152 ± 26.522125.909 ± 26.0995
SecondaryChange From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 520.138 ± 0.16080.150 ± 0.14450.138 ± 0.1458
Week 760.154 ± 0.17440.169 ± 0.15640.147 ± 0.1471
Week 1000.164 ± 0.16050.164 ± 0.15960.156 ± 0.1543
SecondaryChange From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-5.45 ± 25.544-4.50 ± 20.530-1.83 ± 17.191
Week 76-5.92 ± 26.032-6.22 ± 23.133-2.39 ± 19.277
Week 100-8.81 ± 24.313-5.81 ± 21.606-1.56 ± 16.956
SecondaryChange From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-21.81 ± 31.391-27.93 ± 25.263-22.62 ± 26.058
Week 76-26.90 ± 28.965-29.91 ± 24.549-26.13 ± 25.412
Week 100-30.73 ± 30.933-30.65 ± 24.771-27.77 ± 26.119
SecondaryChange From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-22.61 ± 31.979-28.19 ± 25.536-22.79 ± 26.793
Week 76-27.98 ± 29.709-30.27 ± 26.058-26.21 ± 28.115
Week 100-31.87 ± 31.013-31.75 ± 25.615-25.21 ± 26.317
SecondaryChange From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame:
Baseline, Weeks 52, 76 and 100
Reported as:
Mean · units on a scale
Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100
units on a scalePlacebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 52-24.67 ± 27.106-27.16 ± 25.662-26.24 ± 25.113
Week 76-28.05 ± 26.411-31.38 ± 25.449-28.70 ± 24.635
Week 100-30.70 ± 28.632-30.98 ± 26.650-30.68 ± 25.305

Adverse events

Collected over From baseline after the first administration of study drug through End of Study (up to Week 112). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (CP)0/246 (0%)7/246 (2.8%)30/246 (12.2%)
Guselkumab 100 mg q8w (CP)0/248 (0%)3/248 (1.2%)42/248 (16.9%)
Guselkumab 100 mg q4w (CP)0/245 (0%)8/245 (3.3%)52/245 (21.2%)
Placebo to Guselkumab 100 mg q4w (After CP Through Week 112)1/238 (0.4%)16/238 (6.7%)48/238 (20.2%)
Guselkumab 100 mg q8w (Through Week 112)0/248 (0%)22/248 (8.9%)88/248 (35.5%)
Guselkumab 100 mg q4w (Through Week 112)0/245 (0%)22/245 (9%)79/245 (32.2%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPlacebo (CP)Guselkumab 100 mg q8w (CP)Guselkumab 100 mg q4w (CP)Placebo to Guselkumab 100 mg q4w (After CP Through Week 112)Guselkumab 100 mg q8w (Through Week 112)Guselkumab 100 mg q4w (Through Week 112)
Ankle FractureInjury, poisoning and procedural complications0/2461/2480/2450/2383/2481/245
GoitreEndocrine disorders0/2460/2480/2452/2380/2480/245
OsteoarthritisMusculoskeletal and connective tissue disorders0/2460/2481/2452/2380/2482/245
Ischaemic StrokeNervous system disorders0/2460/2481/2450/2380/2482/245
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/2460/2480/2450/2380/2482/245
Cholecystitis ChronicHepatobiliary disorders0/2460/2480/2450/2382/2480/245
PneumoniaInfections and infestations0/2460/2480/2451/2382/2481/245
PericarditisCardiac disorders0/2460/2480/2451/2380/2480/245
CholelithiasisHepatobiliary disorders0/2460/2480/2451/2380/2480/245
Acute Hepatitis CInfections and infestations0/2460/2480/2451/2380/2480/245
Most frequent other events
Most frequent other events
EventPlacebo (CP)Guselkumab 100 mg q8w (CP)Guselkumab 100 mg q4w (CP)Placebo to Guselkumab 100 mg q4w (After CP Through Week 112)Guselkumab 100 mg q8w (Through Week 112)Guselkumab 100 mg q4w (Through Week 112)
Alanine Aminotransferase IncreasedInvestigations11/24615/24822/24511/23829/24831/245
NasopharyngitisInfections and infestations9/24610/24812/2459/23825/24821/245
Upper Respiratory Tract InfectionInfections and infestations8/2467/24813/24518/23824/24820/245
Aspartate Aminotransferase IncreasedInvestigations6/24614/24811/24510/23823/24823/245
HeadacheNervous system disorders2/2466/2483/2457/23816/2487/245
BronchitisInfections and infestations3/2461/24810/2457/23810/24815/245

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Mean46.3 ± 11.6844.9 ± 11.8945.9 ± 11.4745.7 ± 11.68
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Female129119103351
Male117129142388
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Hispanic or Latino1102
Not Hispanic or Latino245247245737
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
American Indian or Alaska Native0000
Asian48315
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White242240242724
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Placebo to Guselkumab 100 mg q4wGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
BULGARIA149629
CZECH REPUBLIC1351533
ESTONIA58518
LATVIA3306
LITHUANIA88420
MALAYSIA36312
POLAND35272385
RUSSIAN FEDERATION9277104273
SPAIN312419
TAIWAN0101
TURKEY28616
UKRAINE658373221
UNITED STATES3126
08

Study locations

138 sites
  • Rheumatology Associates
    Birmingham, Alabama 35205, United States
  • Arizona Arthritis & Rheumatology Associates PC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Clinical Research Center of Connecticut
    Danbury, Connecticut 06810, United States
  • Dawes Fretzin Clinical Research Group LLC
    Indianapolis, Indiana 46256-4697, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Arthritis Consultants
    St Louis, Missouri 63141, United States
  • Austin Regional Clinic
    Austin, Texas 78731-3146, United States
  • Multiprofile Hospital for Active Treatment Plovdiv
    Plovdiv, 4003, Bulgaria
  • Multiprofile Hosptal for Active Treatment Eurohospital Plovdiv
    Plovdiv, 4004, Bulgaria
  • Medical Center Teodora
    Rousse, 7003, Bulgaria
  • Diagnostic Consulting Center No 17
    Sofia, 1505, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • Medical Centre Synexus
    Sofia, 1794, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • Revmaclinic
    Brno, 61141, Czechia
  • Revmacentrum MUDr Mostera s r o
    Brno-Židenice, 615 00, Czechia
  • MUDr Rosypalova s r o
    Ostrava, 70800, Czechia
  • Revmatologicky institut
    Prague, 12850, Czechia
  • Revmatologicka ambulance
    Prague, 14000, Czechia
  • Medical Plus S R O
    Uherské Hradiště, 68601, Czechia
  • PV Medical S R O
    Zlín, 76001, Czechia
  • Parnu Hospital
    Pärnu, 80010, Estonia
  • OU Innomedica
    Tallinn, 10117, Estonia
  • East Tallinn Central Hospital
    Tallinn, 11312, Estonia
  • Clinical Research Centre
    Tartu, 50106, Estonia
  • Daugavpils Regional Hospital
    Daugavpils, LV5417, Latvia
  • Derma Clinic Riga
    Riga, LV1003, Latvia
  • J Kisis Ltd
    Riga, LV1003, Latvia
  • Orto Clinic Ltd
    Riga, LV1005, Latvia
  • Vakk, Jsc
    Kaunas, LT50128, Lithuania
  • Siauliai Republican Hospital, Public Institution
    Šiauliai, LT-76231, Lithuania
  • Central Outpatient Clinic
    Vilnius, LT01117, Lithuania
  • National Osteoporosis Centre
    Vilnius, LT09310, Lithuania
  • Hospital Selayang
    Batu Caves, 68100, Malaysia
  • Hospital Raja Permaisuri Bainun
    Ipoh, 30990, Malaysia
  • Sarawak General Hospital
    Kuching, Sarawak, Malaysia
  • Hospital Melaka
    Malacca, 75400, Malaysia
  • Hospital Putrajaya
    Putrajaya, 62250, Malaysia
  • Hospital Tuanku Jaafar
    Seremban, 70300, Malaysia
  • Szpital Uniwersytecki Nr 2 w Bydgoszczy
    Bydgoszcz, 85 168, Poland
  • NSZOZ Unica CR
    Dąbrówka, 62-069, Poland
  • Centrum Kliniczno Badawcze
    Elblag, 82-300, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Centrum Badawcze Wspolczesnej Terapii
    Lodz, 90-242, Poland
  • Centrum Medyczne AMED oddzial w Lodzi
    Lodz, 91 363, Poland
  • NZOZ Lecznica MAK MED S C
    Nadarzyn, 05-830, Poland
  • Etyka Osrodek Badan Klinicznych
    Olsztyn, 10 117, Poland
  • Centrum Medyczne Hetmanska
    Poznan, 60 218, Poland
  • Lubelskie Centrum Diagnostyczne
    Świdnik, 21 040, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Torun, 87-100, Poland
  • Medycyna Kliniczna
    Warsaw, 00-874, Poland
  • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
    Warsaw, 02 637, Poland
  • Centrum Medyczne AMED Targowek
    Warsaw, 03 291, Poland
  • Wro Medica
    Wroclaw, 51-685, Poland
  • Biogenes Sp z o o
    Wroclaw, 53 224, Poland
  • Chelyabinsk Regional Clinical Dermatovenerological Dispensary
    Chelyabinsk, 454092, Russia
  • Medical and Sanitary Unit ''Severstal''
    Cherepovets, 162600, Russia
  • Regional Clinical Hospital for War Veterans
    Kemerovo, 650000, Russia
  • Medical Centre Maximum Health
    Kemerovo, 650066, Russia
  • Family polyclinic #4
    Korolyov, 141060, Russia
  • Krasnodar Clinical Dermatovenerologic Dispensary
    Krasnodar, 350020, Russia
  • Krasnoyarsk State Medical University
    Krasnoyarsk, 660022, Russia
  • Lipetsk Regional Dermatovenerological Dispensary
    Lipetsk, 398005, Russia
  • Moscow State Medical and Stomatological University
    Moscow, 111398, Russia
  • Clinical Diagnostic Center 'Ultramed'
    Omsk, 644024, Russia
  • Orenburg State Medical University
    Orenburg, 460000, Russia
  • Republican Hospital n.a.V.A.Baranov
    Petrozavodsk, 185019, Russia
  • Rostov Regional Clinical Dermatovenerological Dispensary
    Rostov-on-Don, 344007, Russia
  • Ryazan Regional Clinical Dermatovenerological Dispensary
    Ryazan, 390046, Russia
  • City Clinic №25 - City Rheumatology Centre
    Saint Petersburg, 190068, Russia
  • Leningrad region clinical hospital
    Saint Petersburg, 194291, Russia
  • Saratov Regional Clinical Hospital
    Saratov, 410053, Russia
  • Smolensk regional hospital on Smolensk railway station
    Smolensk, 214025, Russia
  • Tula Regional Clinical Dermatovenerological Dispensary
    Tula, 300053, Russia
  • Regional Clinical Hospital
    Tver', 170036, Russia
  • Republican Clinical Hospital - G.G. Kuvatov
    Ufa, 450005, Russia
  • Clinical Emergency Hospital n.a. N.V. Solovyev
    Yaroslavl, 150003, Russia
  • Clinical Hospital #3
    Yaroslavl, 150007, Russia
  • Clinical Hospital #10
    Yaroslavl, 150023, Russia
  • Research Institute of Dermatovenerology, Immunology
    Yekaterinburg, 620076, Russia
  • Hosp Univ A Coruna
    A Coruña, 15006, Spain
  • Hosp. Univ. de Cruces
    Barakaldo, 48903, Spain
  • Hosp. Univ. de Basurto
    Bilbao, 48013, Spain
  • Hosp Reina Sofia
    Córdoba, 14004, Spain
  • Hosp. Univ. Infanta Leonor
    Madrid, 28031, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Hosp. Regional. Carlos Haya
    Málaga, 29009, Spain
  • Hosp. de Merida
    Mérida, 06800, Spain
  • H.U. Infanta Sofía
    San Sebastián de los Reyes, 28702, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • Hosp. Infanta Luisa
    Seville, 41010, Spain
  • Hosp. Unv. de Valme
    Seville, 414014, Spain
  • Hosp. Univ. Dr. Peset
    Valencia, 46017, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
  • Hosp. Do Meixoeiro
    Vigo, 36214, Spain
  • Hualien Tzu Chi Hospital
    Hualien City, 970, Taiwan
  • Chang Gung Memorial Hospital Kaohsiung Branch
    Kaohsiung City, 833, Taiwan
  • National Cheng Kung University Medical Center
    Tainan, 704, Taiwan
  • Chang Kung Memorial Hospital
    Taipei, 105, Taiwan

Showing the first 100 of 138 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials. Rheumatol Ther. 2026 Feb;13(1):213-229. doi: 10.1007/s40744-025-00812-3. Epub 2025 Dec 15. PubMed 41396391 ↗
  • Crauwels H, Ringold S, Howard S, Van Hartingsveldt B, Smith V, Jett M, Baguet T, Adamson E, Chakravarty SD, Leu JH. Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data. Paediatr Drugs. 2026 Jan;28(1):69-81. doi: 10.1007/s40272-025-00725-2. Epub 2025 Oct 28. PubMed 41152645 ↗
  • Ritchlin CT, Lubrano E, Chimenti MS, Leibowitz E, Sharaf M, Rampakakis E, Nantel F, Lavie F, Deodhar A. Guselkumab Efficacy in Biologic-Naive Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study. Rheumatol Ther. 2025 Oct;12(5):925-940. doi: 10.1007/s40744-025-00777-3. Epub 2025 Jul 21. PubMed 40690163 ↗
  • Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty SD, Lavie F, Rahman P. Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial. Ther Adv Musculoskelet Dis. 2024 Oct 27;16:1759720X241283536. doi: 10.1177/1759720X241283536. eCollection 2024. PubMed 39493888 ↗
  • Mease P, Korotaeva T, Shesternya P, Kokhan M, Rukavitsyn A, Vasilchenkov D, Sharaf M, Lavie F, Deodhar A. Guselkumab in Biologic-Naive Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials. Rheumatol Ther. 2024 Dec;11(6):1551-1567. doi: 10.1007/s40744-024-00713-x. Epub 2024 Sep 25. PubMed 39320583 ↗
  • Curtis JR, Deodhar A, Soriano ER, Rampakakis E, Shawi M, Shiff NJ, Han C, Tillett W, Gladman DD. Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials. Rheumatol Ther. 2024 Dec;11(6):1501-1517. doi: 10.1007/s40744-024-00702-0. Epub 2024 Sep 11. PubMed 39261446 ↗
  • Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Chakravarty SD, Rampakakis E, Shawi M, Schiopu E, Merola JF, McInnes IB, Deodhar A. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clin Rheumatol. 2024 Aug;43(8):2551-2563. doi: 10.1007/s10067-024-06991-8. Epub 2024 Jun 7. PubMed 38844682 ↗
  • Baraliakos X, Gladman DD, Chakravarty SD, Gong C, Shawi M, Rampakakis E, Kishimoto M, Soriano ER, Mease PJ. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatol Adv Pract. 2024 Apr 23;8(2):rkae058. doi: 10.1093/rap/rkae058. eCollection 2024. PubMed 38765190 ↗
  • Warren RB, McInnes IB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, Mease PJ. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Jun;11(3):829-839. doi: 10.1007/s40744-024-00659-0. Epub 2024 Mar 15. PubMed 38488975 ↗
  • Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, Sherlock JP, Kollmeier AP, Xu XL, Sheng S, Ritchlin CT, McGonagle D. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clin Rheumatol. 2024 May;43(5):1591-1604. doi: 10.1007/s10067-024-06921-8. Epub 2024 Mar 12. PubMed 38472528 ↗
  • Curtis JR, McInnes IB, Rahman P, Gladman DD, Peterson S, Yang F, Adejoro O, Kollmeier AP, Shiff NJ, Han C, Shawi M, Tillett W, Mease PJ. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatol Ther. 2024 Apr;11(2):425-441. doi: 10.1007/s40744-024-00642-9. Epub 2024 Feb 22. PubMed 38386178 ↗
  • Coates LC, Rahman P, Mease PJ, Shawi M, Rampakakis E, Kollmeier AP, Xu XL, Chakravarty SD, McInnes IB, Tam LS. Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study. BMC Rheumatol. 2024 Feb 4;8(1):6. doi: 10.1186/s41927-024-00375-w. PubMed 38310261 ↗
  • Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31. PubMed 37906417 ↗
  • Mease PJ, Gladman DD, Poddubnyy D, Chakravarty SD, Shawi M, Kollmeier AP, Xu XL, Xu S, Deodhar A, Baraliakos X. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study. Rheumatol Ther. 2023 Dec;10(6):1637-1653. doi: 10.1007/s40744-023-00592-8. Epub 2023 Oct 11. PubMed 37819505 ↗
  • Gottlieb AB, McInnes IB, Rahman P, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, Lavie F, Mease PJ. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023 Feb;9(1):e002789. doi: 10.1136/rmdopen-2022-002789. PubMed 36828643 ↗
  • Rahman P, Boehncke WH, Mease PJ, Gottlieb AB, McInnes IB, Shawi M, Wang Y, Sheng S, Kollmeier AP, Theander E, Yu J, Leibowitz E, Marrache AM, Coates LC. Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis. J Rheumatol. 2023 Jun;50(6):769-780. doi: 10.3899/jrheum.220928. Epub 2023 Jan 15. PubMed 36642439 ↗
  • Curtis JR, McInnes IB, Rahman P, Gladman DD, Peterson S, Agarwal P, Yang F, Kollmeier AP, Hsia EC, Shiff NJ, Zhou B, Han C, Shawi M, Tillett W, Mease PJ. The Effect of Guselkumab on Work Productivity in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial. Adv Ther. 2022 Oct;39(10):4613-4631. doi: 10.1007/s12325-022-02270-7. Epub 2022 Aug 10. PubMed 35947349 ↗
  • Curtis JR, McInnes IB, Rahman P, Gladman DD, Yang F, Peterson S, Agarwal P, Kollmeier AP, Hsia EC, Han C, Shiff NJ, Shawi M, Tillett W, Mease PJ. The Effect of Guselkumab on General Health State in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial. Adv Ther. 2022 Oct;39(10):4632-4644. doi: 10.1007/s12325-022-02269-0. Epub 2022 Aug 10. PubMed 35947348 ↗
  • Coates LC, Ritchlin CT, Gossec L, Helliwell PS, Rahman P, Kollmeier AP, Xu XL, Shawi M, Karyekar CS, Contre C, Noel W, Sheng S, Wang Y, Xu S, Mease PJ. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2023 Feb 1;62(2):606-616. doi: 10.1093/rheumatology/keac375. PubMed 35766811 ↗
  • Schett G, Loza MJ, Palanichamy A, FitzGerald O, Ritchlin C, Bay-Jensen AC, Nielsen SH, Gao S, Hsia EC, Kollmeier AP, Xu XL, Baribaud F, Sweet K. Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2). Rheumatol Ther. 2022 Aug;9(4):1017-1030. doi: 10.1007/s40744-022-00444-x. Epub 2022 Mar 30. PubMed 35352313 ↗
  • Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Schiopu E, Chakravarty SD, Kollmeier AP, Xu XL, Shawi M, Jiang Y, Sheng S, Wang Y, Xu S, Merola JF, McInnes IB, Deodhar A. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 2022 Mar;8(1):e002195. doi: 10.1136/rmdopen-2022-002195. PubMed 35296534 ↗
  • Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A, Kollmeier AP, Hsia EC, Zhou B, Lin X, Shawi M, Karyekar CS, Han C. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021 Jul 14;23(1):190. doi: 10.1186/s13075-021-02554-3. PubMed 34261541 ↗
  • Sweet K, Song Q, Loza MJ, McInnes IB, Ma K, Leander K, Lakshminarayanan V, Franks C, Cooper P, Siebert S. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open. 2021 May;7(2):e001679. doi: 10.1136/rmdopen-2021-001679. PubMed 34011674 ↗
  • Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. J Rheumatol. 2021 Dec;48(12):1815-1823. doi: 10.3899/jrheum.201532. Epub 2021 May 1. PubMed 33934076 ↗
  • McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Ritchlin CT, Rahman P, Mease PJ. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology (Oxford). 2021 Nov 3;60(11):5337-5350. doi: 10.1093/rheumatology/keab285. PubMed 33822898 ↗
  • McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD, Xu XL, Subramanian RA, Agarwal P, Sheng S, Jiang Y, Zhou B, Zhuang Y, van der Heijde D, Mease PJ. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. Arthritis Rheumatol. 2021 Apr;73(4):604-616. doi: 10.1002/art.41553. Epub 2021 Mar 17. PubMed 33043600 ↗
  • Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13. PubMed 32178766 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Feb 2019, 19 months.

Results were first posted in Nov 2020, 1 year 8 months after primary completion. A results delay was requested in Feb 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2017
First posted
May 18, 2017
StartActual
Jul 12, 2017
Primary completionActual
Feb 25, 2019
CompletionActual
Nov 10, 2020
Results delay requested
Feb 24, 2020
Results first posted
Nov 5, 2020
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03158285
Responsible party
Sponsor
First posted
May 18, 2017
Start date
Jul 12, 2017
Primary completion
Feb 25, 2019
Completion
Nov 10, 2020
Results posted
Nov 5, 2020
Last update
Jun 2, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion